<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Curr Med Chem</journal-id><journal-id journal-id-type="publisher-id">CMC</journal-id><journal-title-group><journal-title>Current Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="ppub">0929-8673</issn><issn pub-type="epub">1875-533X</issn><publisher><publisher-name>Bentham Science Publishers Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">3228236</article-id><article-id pub-id-type="publisher-id">CMC-18-2686</article-id><article-id pub-id-type="doi">10.2174/092986711796011229</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Shuttleworth</surname><given-names>S.J</given-names></name><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Silva</surname><given-names>F.A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Cecil</surname><given-names>A.R.L</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tomassi</surname><given-names>C.D</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hill</surname><given-names>T.J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Raynaud</surname><given-names>F.I</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Clarke</surname><given-names>P.A</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Workman</surname><given-names>P</given-names></name><xref ref-type="author-notes" rid="fn1">*</xref><xref ref-type="aff" rid="aff2">2</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Karus Therapeutics Ltd., Southampton Science Park, 2 Venture Road, Southampton, SO16 7NP, UK</aff><aff id="aff2"><label>2</label>Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK</aff><author-notes><corresp id="cor1"><label>*</label>Address correspondence to these authors at the Karus Therapeutics Ltd., Southampton Science Park, 2 Venture Road, Southampton, SO16 7NP, UK; Tel: +44 (0) 23 8011 1360; Fax: +44 (0) 23 8001 5911: E-mail: <email xlink:href="s.shuttleworth@karustherapeutics.com">s.shuttleworth@karustherapeutics.com</email></corresp><fn id="fn1"><p><text><SENT sid="1" pm="."><plain>Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK; Tel: +44 (0) 20 8722 4301; Fax: +44 (0) 20 8722 4324: E-mail: paul.workman@icr.ac.uk </plain></SENT>
</text></p></fn></author-notes><pub-date pub-type="ppub"><month>6</month><year>2011</year></pub-date><volume>18</volume><issue>18</issue><fpage>2686</fpage><lpage>2714</lpage><history><date date-type="received"><day>14</day><month>2</month><year>2011</year></date><date date-type="rev-recd"><day>13</day><month>5</month><year>2011</year></date><date date-type="accepted"><day>15</day><month>5</month><year>2011</year></date></history><permissions><copyright-statement>© 2011 Bentham Science Publishers Ltd.</copyright-statement><copyright-year>2011</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<uri xlink:type="simple" xlink:href="http://creativecommons.org/licenses/by/2.5/">http://creativecommons.org/licenses/by/2.5/</uri>), which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="2" pm="."><plain>The phosphoinositide 3-kinases (PI3Ks) constitute an important family of lipid kinase enzymes that control a range of cellular processes through their regulation of a network of signal transduction pathways, and have emerged as important therapeutic targets in the context of cancer, inflammation and cardiovascular diseases. </plain></SENT>
<SENT sid="3" pm="."><plain>Since the mid-late 1990s, considerable progress has been made in the discovery and development of small molecule ATP-competitive PI3K inhibitors, a number of which have entered early phase human trials over recent years from which key clinical results are now being disclosed. </plain></SENT>
<SENT sid="4" pm="."><plain>This review summarizes progress made to date, primarily on the discovery and characterization of class I and dual class I/IV subtype inhibitors, together with advances that have been made in translational and clinical research, notably in cancer. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group><title>Keywords</title><kwd>PI3K</kwd><kwd>inhibitor</kwd><kwd>p110α</kwd><kwd>p110β</kwd><kwd>p110δ</kwd><kwd>p110γ</kwd><kwd>mTOR</kwd><kwd>cancer</kwd><kwd>inflammation</kwd><kwd>cardiovascular.</kwd></kwd-group></SecTag></article-meta></front><body><SecTag type="INTRO"><sec><label>1</label><title><text><SENT sid="5" pm="."><plain>INTRODUCTION </plain></SENT>
</text></title><p><text><SENT sid="6" pm="."><plain>The PI3K superfamily has, over the past 15 years, become one of the most extensively studied classes of therapeutic targets in small molecule drug discovery, particularly in oncology [1-4]. </plain></SENT>
<SENT sid="7" pm="."><plain>Four distinct PI3K subfamilies exist – commonly referred to as class I, II, III and IV – based upon their substrate specificities, primary structures, modes of regulation and domain content. </plain></SENT>
<SENT sid="8" pm="."><plain>Of these, it is the class I isoforms, p110α, p110β, p110δ and p110γ, together with the class IV PI3K-related kinase (PIKK), mTOR [5,6], which have been the most intensively examined targets in the small molecule therapeutic arena, and which form the principal subject of this present discussion. </plain></SENT>
</text></p></sec></SecTag><sec><label>2</label><title><text><SENT sid="9" pm="."><plain>CLASS I PI3K ISOFORMS AND mTOR IN CHRONIC DISEASE: POTENTIAL FOR SMALL MOLECULE INHIBITORS </plain></SENT>
</text></title><p><text><SENT sid="10" pm="."><plain>The majority of small molecule discovery research in the PI3K field has, to date, centred on class I inhibitors for the treatment of cancer. </plain></SENT>
<SENT sid="11" pm="."><plain>The key mechanistic rationale for this stems from the class I PI3K/AKT pathway being dysregulated in a tissue-diverse range of tumours [1-4, 7,8]. </plain></SENT>
<SENT sid="12" pm="."><plain>The phosphatase PTEN, the negative regulator of PI3K, is one of the most commonly mutated proteins in human malignancy [9]. </plain></SENT>
<SENT sid="13" pm="."><plain>Furthermore, the gene encoding for the p110α subunit, PIK3CA, is amplified, overexpressed and frequently mutated in many cancers [10]; critically, these mutations have been shown to reduce cellular dependence on growth factors, to attenuate apoptosis, and to facilitate tumour invasiveness. </plain></SENT>
<SENT sid="14" pm="."><plain>Additionally, a greater understanding of the specific roles of the p110α and p110β isoforms in tumourigenesis has recently been established: it has been shown that p110α is critical for the growth of tumours driven by PIK3CA mutations as well as oncogenic receptor tyrosine kinases and RAS, whilst p110β is the principal isoform involved in mediating PTEN-deficient tumourigenesis [11-13]. </plain></SENT>
<SENT sid="15" pm="."><plain>In addition, p110δ has also emerged as a key therapeutic target for haematological malignancies [14,15], notably acute myeloid leukaemia (AML), and there is also some evidence that this isoform is upregulated in melanoma and breast cancer, and is overexpressed in neuroblastoma [4]. </plain></SENT>
<SENT sid="16" pm="."><plain>Furthermore, there is potential for all the class I PI3Ks to be activated in cancer cells through mutation of the p85 regulatory subunits. </plain></SENT>
<SENT sid="17" pm="."><plain>Consequently, inhibition of class IA PI3Ks – p110α, p110β and p110δ – represents an important strategy for the development of novel cancer therapeutics, and, moving forward, is anticipated to have a significant impact on the discovery and development of new personalized medicines in the oncology setting. </plain></SENT>
</text></p><p><text><SENT sid="18" pm="."><plain>In addition to PTEN-null tumours, p110β has been pursued as a target for antithrombotic therapy [16], and there is also growing evidence that p110β inhibitors could have significant therapeutic potential in autoimmune diseases [17-19]. </plain></SENT>
<SENT sid="19" pm="."><plain>Furthermore, p110γ has been reported to play an important role in mast cell, eosinophil and neutrophil function [20]. </plain></SENT>
<SENT sid="20" pm="."><plain>Interestingly, the p110γ isoform was the first of the PI3K enzyme family for which a liganded crystal structure was resolved [21], and it has since been the subject of a number of small molecule R&amp;D activities [4]. </plain></SENT>
<SENT sid="21" pm="."><plain>However, at the time of writing, there are no examples of p110γ-specific inhibitors to have entered clinical development. </plain></SENT>
<SENT sid="22" pm="."><plain>By contrast, the p110δ subtype, which has also been shown to play a central function in the recruitment and activation of a range of immune and inflammatory cells [22-24], has become a hotly pursued target in small molecule drug discovery circles. </plain></SENT>
<SENT sid="23" pm="."><plain>Co-crystal structures of this isoform were recently resolved [25], and there are several p110δ-targeted inhibitors that are currently in preclinical development – with two having now entered early phase clinical studies – for the treatment of haematological cancer and immune-inflammatory disorders [4,26]. </plain></SENT>
</text></p><p><text><SENT sid="24" pm="."><plain>Finally, there has been significant recent progress made in the discovery of new small molecules that target the PIKK sub-family member, mTOR. </plain></SENT>
<SENT sid="25" pm="."><plain>This protein was originally discovered in the 1990s, when the mechanism of action of rapamycin, a macrolide-based natural product with immunosuppressant activity, was elucidated [27]. </plain></SENT>
<SENT sid="26" pm="."><plain>Rapamycin and derivatives thereof bind with high afﬁnity to the immunophilin FK506-binding protein-12 (FKBP12), forming a complex that selectively inhibits mTORC1 downstream signalling to elements involved in growth control, and they have since been evaluated as agents for the treatment of solid tumours [4]. </plain></SENT>
<SENT sid="27" pm="."><plain>In addition, recent progress been made in targeting the ATP-binding site of mTOR with small molecule inhibitors that exhibit anti-tumour activity. </plain></SENT>
<SENT sid="28" pm="."><plain>Of particular significance to this present review, however, is the discovery and development of a number of small molecules that dually inhibit class I PI3Ks – particularly p110α – together with mTOR for the treatment of cancer, and these are discussed below. </plain></SENT>
<SENT sid="29" pm="."><plain>Inhibitors of class IV PI3Ks involved in DNArepair are also of interest in cancer, but will not be covered here </plain></SENT>
</text></p></sec><sec><label>3</label><title><text><SENT sid="30" pm="."><plain>ISOFORM-SELECTIVE PI3K INHIBITORS: HISTORICAL LANDSCAPE AND RECENT PROGRESS </plain></SENT>
</text></title><p><text><SENT sid="31" pm="."><plain>Since the discovery of LY294002 1 [28] and the elucidation of the mechanism of action of the natural product Wortmannin 2 [29], both of which display activity against the class I PI3K isoforms, considerable progress has been made in the development of a plethora of structurally-diverse inhibitors that possess distinct subtype selectivity profiles. </plain></SENT>
<SENT sid="32" pm="."><plain>The properties of a number of these compounds – including some that have advanced into clinical development – have been reviewed extensively elsewhere [4, 30-32]. </plain></SENT>
<SENT sid="33" pm="."><plain>Examples include the reversible, ATP-competitive p110α/pan-class I selective inhibitors GDC-0941, 3 [33,34], XL147, 4 [35], GSK1059615, 5 [36], and ZSTK474, 6 [37]; the irreversible p110α inhibitor PX-866, 7 [29]; the p110δ-selective inhibitor CAL-101, 8 [38]; the dual pan-class I/mTOR inhibitors SF1126, 9 [39], NVP-BEZ235, 10 [40], XL765, 11 [41] and GSK1059615, 12 [36]; the dual p110δ/γ inhibitor TG100115, 13 [29]; and the p110β-selective TGX-221, 14 [42]. </plain></SENT>
<SENT sid="34" pm="."><plain>Clinical data for several of these agents are summarized in Section 5. </plain></SENT>
<SENT sid="35" pm="."><plain>Additional small molecule PI3K inhibitors reported to be in pre-clinical discovery or development as of mid-2009 include compounds 14 through 36 (Table 1), the biochemical, cellular and pharmacological properties of which have been chronicled previously [4], and which will not be discussed here. </plain></SENT>
<SENT sid="36" pm="."><plain>Rather, we illustrate the impact of structure-based drug design and focus on providing details of compounds disclosed in the primary and patent literature since that time. </plain></SENT>
<SENT sid="37" pm="."><plain>The chemical structures of these more recent compounds are listed in Table 2. </plain></SENT>
</text></p><sec><label>3.1</label><title><text><SENT sid="38" pm="."><plain>Pan-Class I, Dual Pan-Class I/mTOR and Dual p110α/mTOR Inhibitors </plain></SENT>
</text></title><sec><label>3.1.1</label><title><text><SENT sid="39" pm="."><plain>Impact of Co-Crystal Structure Elucidation on the Design of Novel Small Molecule PI3K Inhibitors </plain></SENT>
</text></title><p><text><SENT sid="40" pm="."><plain>In considering the overall progress on the fascinating journey from early chemical tools to potent, selective and drug-like PI3K inhibitors that are now in the clinic, the exploitation of X-ray crystal structures of p110 catalytic domains to enable structure-based design has been especially valuable [3]. </plain></SENT>
<SENT sid="41" pm="."><plain>As an example, Fig. </plain></SENT>
<SENT sid="42" pm="."><plain>(1) shows the co-crystal structure of the clinical pan-class I PI3K drug GDC-0941 3 bound to human p110γ. </plain></SENT>
<SENT sid="43" pm="."><plain>Overall there is a snug fit of the inhibitor in the ATP binding site and key features of the tridentate binding mode are: 1) the use of the morpholine oxygen to form a hydrogen bonding interaction with the amide of the hinge region Val 882 that is also bound by the adenine in ATP (left-hand side), representing an example of the privileged aryl morpholine structure that is seen commonly in many PI3K inhibitors; 2) the indazole moiety (right-hand side) which fits deep in the so-called affinity pocket and in which the two indazole nitrogen atoms form hydrogen bonds with the hydroxyl group of Tyr 867 and the carboxylate of Asp 841; and 3) the 4-methanesulfonyl–piperazin-1-ylmethyl group (projecting out of the plane, centre) that points to the solvent channel and has a solubilising function, but also makes additional binding interactions with the protein through the piperazine ring lying close to the side chain of Met 804 and the sulfonyl group forming hydrogen bonds with Ala 805 and Lys 802 at the mouth of the ATP pocket. </plain></SENT>
<SENT sid="44" pm="."><plain>Furthermore, the thienopyrimidine core is sandwiched between Met 953 and Ile 963 (forming the floor of the ATP pocket) and the side chains of Met 804, Trp 812 and Ile 831 (which form the ceiling of the ATP site) [3,33, 34]. </plain></SENT>
</text></p><p><text><SENT sid="45" pm="."><plain>Structural biology insights are now facilitating both the design of new PI3K inhibitors with distinct isoform selectivities, and the interpretation of the binding properties of existing small molecules inhibitors of the superfamily. </plain></SENT>
<SENT sid="46" pm="."><plain>As an example of the impact of crystal structures and the potential for structure-based design, most PI3K inhibitors bind to p110γ in a flat orientation, in the same plane as that adopted by the adenine of ATP; in contrast, an inducible and conformationally flexible specificity pocket is involved in the selectivity of compounds that act preferentially on p110δ, involving amino acid residues that are distal to the ATP binding site and that are more variable between p110 isoforms [106,107]. </plain></SENT>
<SENT sid="47" pm="."><plain>The p110δ isoform is more conformationally flexible than p110β and p110γ, and inhibitors preferring p110δ adopt a propeller shape which allows them to induce and access the specificity pocket. </plain></SENT>
<SENT sid="48" pm="."><plain>The specificity pocket appears to be more easily inducible and accessible in p110δ compared to p110γ and, moreover, it is predicted that p110α will be unable to undergo this conformational rearrangement. </plain></SENT>
</text></p></sec><sec><label>3.1.2</label><title><text><SENT sid="49" pm="."><plain>Recent Examples of New ATP-Competitive PI3K Inhibitors </plain></SENT>
</text></title><p><text><SENT sid="50" pm="."><plain>As mentioned above, we have previously chronicled details of the in vitro and in vivo properties of a plethora of diverse small molecule PI3K inhibitors developed up to mid-2009 (Table 1, compounds 14-36) [4]. </plain></SENT>
<SENT sid="51" pm="."><plain>A number of those compounds are now in clinical development, and are discussed in further detail below. </plain></SENT>
<SENT sid="52" pm="."><plain>Over the past 18 months, the field has continued to develop at a substantial pace, with many examples of novel ATP-competitive inhibitors having been disclosed in the literature during that time. </plain></SENT>
<SENT sid="53" pm="."><plain>There has, in particular, been significant progress made in the development of pan-class I/mTOR dual inhibitors, and of class I inhibitors with distinct isoform selectivity profiles. </plain></SENT>
<SENT sid="54" pm="."><plain>The dominant therapeutic focus continues to be cancer, although inhibitors of other isoforms – particularly p110δ and p110γ – with utility in the treatment of immune-inflammatory diseases – have also been developed. </plain></SENT>
<SENT sid="55" pm="."><plain>One significant development in the PI3K arena is the emerging, compelling evidence that targeting of p110β with selective small molecule inhibitors may provide therapeutic benefit in the treatment of autoimmune diseases [19], as well as in the treatment of specific (PTEN-null) tumour types [12]. </plain></SENT>
<SENT sid="56" pm="."><plain>This is a relatively unexplored area, however, and p110β inhibitors are scarce. </plain></SENT>
<SENT sid="57" pm="."><plain>However, we expect the discovery and development of such inhibitors to be the subject of increasing focus over the coming years. </plain></SENT>
</text></p><p><text><SENT sid="58" pm="."><plain>Table 2 lists the chemical structures of compounds 37-87, which represent a new series of small molecule PI3K inhibitors that have been reported in the literature during the last 18 months. </plain></SENT>
<SENT sid="59" pm="."><plain>These are predominantly reversible, ATP-competitive inhibitors, and many feature the aryl-morpholine structural unit, an established hinge-targeted structural motif. </plain></SENT>
<SENT sid="60" pm="."><plain>It is clear in these examples, however, that subtle structural modifications can lead to quite dramatic changes to class I and IV subtype selectivity. </plain></SENT>
</text></p><p><text><SENT sid="61" pm="."><plain>Yuan and co-workers have developed a series of potent demethoxyviridin derivatives which display significantly improved in vivo stability compared with demethoxyviridin. </plain></SENT>
<SENT sid="62" pm="."><plain>It was observed that esterification of the C1 position of demethoxyviridin led to an increase in serum half-life to two hours from 26 minutes; furthermore, conjugate addition with glycine furnished a derivative, 37, whose half-life was 218 minutes, and which displayed an IC50 of 44nM [62]. </plain></SENT>
</text></p><p><text><SENT sid="63" pm="."><plain>Researchers at the University of Auckland have disclosed results from their virtual screening approaches to the discovery of new chemical entities targeting PI3K activity [63]. </plain></SENT>
<SENT sid="64" pm="."><plain>Following in silico screening of the ZINC compound database, which comprises 2.5 million compounds, a total of 89 new chemotypes were identified; biochemical screening subsequently led to the discovery of seven new compounds displaying activity between 1 and 100µM of which 38 was the most active, displaying pan-PI3K inhibition with an IC50 of 0.9µM, 3µM, 0.9µM and 4µM against p110α, β, δ and γ respectively. </plain></SENT>
</text></p><p><text><SENT sid="65" pm="."><plain>Gilbert and colleagues at Wyeth have reported the discovery of two structurally-related series based on purine [3,4-d]pyrimidines and pyrazolo [3,4-d]pyrimidines, exemplified by 39 and 40 respectively [64]. </plain></SENT>
<SENT sid="66" pm="."><plain>Interestingly, subtle structural changes were seen to lead to dramatic alterations in subtype selectivity: compound 39 had an IC50 of 58nM against p110α, and displayed good selectivity over p110γ and mTOR, whereas 40 showed more dual p110α/mTOR activity (IC50 = 32nM and 83nM respectively), though with high selectivity over p110γ (IC50 = 2367nM). </plain></SENT>
</text></p><p><text><SENT sid="67" pm="."><plain>Venkatesan and co-workers at Wyeth have outlined the development of imidazolopyrimidine derivatives exhibiting selective inhibition of both the class I isoforms and mTOR [65]. </plain></SENT>
<SENT sid="68" pm="."><plain>An example of such a compound is 41, which had an IC50 of 16nM and 265nM against p110α and p110γ respectively, but was inactive against mTOR. </plain></SENT>
<SENT sid="69" pm="."><plain>In a separate report, the same team also described the design, synthesis, and characterization of the highly potent bismorpholino-1,3,5-triazine derivative 42 (PKI-587), a potent dual class I PI3K/mTOR inhibitor [66]. </plain></SENT>
<SENT sid="70" pm="."><plain>This compound was seen to inhibit cell survival and proliferation, and to increase apoptosis in vitro and in vivo. </plain></SENT>
<SENT sid="71" pm="."><plain>PKI-587 also exerted potent anti-tumour efficacy in preclinical subcutaneous and orthotopic tumour xenograft models, and has now entered phase I clinical trials. </plain></SENT>
<SENT sid="72" pm="."><plain>A further report from Venkatesan et al. outlined the development of a related series of 1,3,5-triazine derivatives, targeted with the aim of improving the physicochemical properties of PKI-587 [67]. </plain></SENT>
<SENT sid="73" pm="."><plain>Incorporation of a 3-oxa-8-azabicyclo[3.2.1]octane group in place of a morpholine resulted in the design of PKI-179, 43, which displayed potent in vitro activity (IC50 = 8nM, 74nM, 0.42nM against p110α, p110γ and mTOR respectively). </plain></SENT>
<SENT sid="74" pm="."><plain>PKI-179 also has high oral bioavailability, and anti-tumour efficacy in the MDA-361 human breast tumour xenograft model. </plain></SENT>
<SENT sid="75" pm="."><plain>The compound was subsequently advanced into a phase I solid tumour study, though this trial has now been terminated. </plain></SENT>
<SENT sid="76" pm="."><plain>In a subsequent disclosure, it was revealed that, in in vitro studies, a major metabolite of PKI-179, 44, was generated following incubation in human liver microsomes [68]; Chen and co-workers confirmed that this metabolite displayed comparable in vitro potency to that of PKI-179. </plain></SENT>
</text></p><p><text><SENT sid="77" pm="."><plain>Dehnhardt et al. at Wyeth have described the discovery of a series of triazolopyrimidines, which led to the development of PKI-402, 45, a dual p110α/mTOR inhibitor (respective IC50s = 1.4nM and 1.7nM). </plain></SENT>
<SENT sid="78" pm="."><plain>PKI-402 displayed high anti-proliferative activity in tumour cell lines, induced apoptosis in vitro, and conferred potent anti-tumour efficacy in several tumour xenograft models [69]. </plain></SENT>
<SENT sid="79" pm="."><plain>In a further report, Zhang and co-workers at Wyeth outlined the discovery of a novel class of 5-ureidobenzofuran-3-one indoles also displaying potent p110α/mTOR activity, exemplified by 46, which displayed very high biochemical activity (IC50 = 0.2nM and 0.3nM against p110α and mTOR respectively) with concomitant in vitro tumour cell growth inhibition (GI50 for inhibition of the growth of PC3 prostate cancer cells = 10nM). </plain></SENT>
<SENT sid="80" pm="."><plain>Compound 46 also displayed potent anti-tumour efficacy in the MDS-361 breast tumour xenograft model following daily iv dosing [70]. </plain></SENT>
</text></p><p><text><SENT sid="81" pm="."><plain>A report from Venkatesan et al. outlined the synthesis and characterization of 7H-pyrrolo[2,3-H]quinazolines with PI3K and mTOR activity [71]. </plain></SENT>
<SENT sid="82" pm="."><plain>The compound with the highest reported mTOR activity was 47 (IC50 = 2nM), though the structrually-related 48 displayed potent p110α and p110γ activity (respective IC50 values of 22nM and 142nM). </plain></SENT>
<SENT sid="83" pm="."><plain>Compound 48 also conferred potent in vitro tumour growth inhibition (GI50 = 48nM, 70nM and 160nM against LNCap, MDA468 and hSMG1 cancer cells respectively). </plain></SENT>
</text></p><p><text><SENT sid="84" pm="."><plain>A series of 4-morpholinopyrrolopyrimidine derivatives was reported by Chen et al. to display both p110α and dual p110α/mTOR activity. </plain></SENT>
<SENT sid="85" pm="."><plain>Compound 49 was found to be a selective and potent p110( inhibitor, with an IC50 of 21nM, whilst 50 had an IC50 of 0.9nM and 0.6nM respectively against p110α and mTOR [72]. </plain></SENT>
</text></p><p><text><SENT sid="86" pm="."><plain>Chen and colleagues have disclosed the discovery of a series of 2-aryl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)morpholines with activity against class I PI3Ks and mTOR. </plain></SENT>
<SENT sid="87" pm="."><plain>Compound 51 showed potent inhibition of p110α and p110γ, with respective IC50 values of 0.9nM and 14nM. </plain></SENT>
<SENT sid="88" pm="."><plain>The tertiary amide derivative, 52, was reported to display highly potent biochemical inhibition of mTOR inhibition (IC50 of 300pM) [73]. </plain></SENT>
</text></p><p><text><SENT sid="89" pm="."><plain>Montagne et al. at Merck-Serono have reported the synthesis of a library of compounds based upon 2-morpholino-pyrido[3,2-d]pyrimidines which exhibit PI3K activity. </plain></SENT>
<SENT sid="90" pm="."><plain>One example, 53, was reported to have an IC50 of 8nM [74]. </plain></SENT>
<SENT sid="91" pm="."><plain>In another report, Cardin and colleagues at Millennium disclosed the production of another targeted library, based upon a thiophene core,with PI3K activities in the 100nM-5µM IC50 range being obtained, including for compound 54 [75]. </plain></SENT>
<SENT sid="92" pm="."><plain>An additional library of thiophene derivatives designed by researchers at Millennium, with similar biochemical potencies, was reported by Renou et al., exemplified by 55 [76]. </plain></SENT>
</text></p><p><text><SENT sid="93" pm="."><plain>Bo et al. at Amgen have disclosed the development of tri-substituted pyridine derivatives displaying dual PI3K/mTOR activity [77], a key example of which was 56. </plain></SENT>
<SENT sid="94" pm="."><plain>This compound was reported to have an IC50 of 1.3nM and 0.6nM against p110α and mTOR respectively, and displayed high anti-proliferative potency in U87 glioma tumour cells (IC50 = 5.3nM). </plain></SENT>
<SENT sid="95" pm="."><plain>In a further report from Amgen, a series of di-substituted benzimidazole analogues were disclosed by Boezio and colleagues, displaying potent biochemical mTOR activity [78]. </plain></SENT>
<SENT sid="96" pm="."><plain>It was observed that specific substitution patterns governed selectivity for class I PI3Ks and mTOR; compound 57 displayed dual mTOR/p110α inhibition (IC50 = 0.27nM and 0.65nM respectively), and potent growth inhibition activity in PTEN negative U87 cells (IC50 = 5nM). </plain></SENT>
</text></p><p><text><SENT sid="97" pm="."><plain>A new class of imidazo1,2-apyridine derivatives with anti-tumour activity has been disclosed by Bo et al. at Amgen [79]. </plain></SENT>
<SENT sid="98" pm="."><plain>Compound 58 displayed potent biochemical activity against p110α (Ki = 1nM) and mTOR (IC50 = 15nM), and potently inhibited U87 glioma tumour cell proliferation (IC50 = 7nM). </plain></SENT>
</text></p><p><text><SENT sid="99" pm="."><plain>Rewcastle et al. have disclosed a series of morpholino-triazines with specificity for p110α, and which exhibit potent in vitro anti-tumour efficacy [80]. </plain></SENT>
<SENT sid="100" pm="."><plain>A key example is compound 59, which was seen to be selective over p110β and p110γ (0.1 &lt; IC50 &lt; 1 µM), and inhibited NZOV9 cell proliferation with an IC50 &lt; 0.1 µM [80]. </plain></SENT>
</text></p><p><text><SENT sid="101" pm="."><plain>Heffron et al. have disclosed the characterization of GNE-477, 60. </plain></SENT>
<SENT sid="102" pm="."><plain>This compound was seen to exhibit dual p110α/mTOR inhibition (IC50 = 4 and 21nM, respectively), and displayed potent in vivo tumour growth inhibition in the PC3 prostate tumour xenograft model [81]. </plain></SENT>
</text></p><p><text><SENT sid="103" pm="."><plain>Cai and colleagues at Curis have reported the generation of a targeted array of small molecules based on the deazapurine, furopyrimidine and thienopyrimidine scaffolds that possess zinc-binding moieties, and which display potent inhibition of p110α, mTOR and histone deacetylase (HDAC) [82]. </plain></SENT>
<SENT sid="104" pm="."><plain>A representative example is 61, which showed potent inhibition of all three enzymes (IC50 &lt; 100nM), and antiproliferative activities (GI50 &lt; 100nM) in a tissue-diverse panel of tumour cells in vitro, including the HCT-116, BT-474, SK-MEL-28, and H1993 cancer lines. </plain></SENT>
</text></p><p><text><SENT sid="105" pm="."><plain>Baik and et al. at Exelixis have developed a series of pyridopyrimidinones with class I PI3K/mTOR activity [83]. </plain></SENT>
<SENT sid="106" pm="."><plain>A representative example, 62, was reported to display p110α, p110β and mTOR inhibition with IC50 values of 5.5nM, 52.1nM and 2.6nM respectively, and GI50 values of 15.8nM and 97.8nM respectively in PC3 prostate and MCF7 breast cancer cells. </plain></SENT>
</text></p><p><text><SENT sid="107" pm="."><plain>Cheng and colleagues at Pfizer have disclosed the development of PF-04691502, 63, a dual inhibitor of p110α (IC50 = 0.57nM) and mTOR (IC50 =16nM), with high in vivo efficacy in the p110α mutant SKOV3 ovarian tumour xenograft model. </plain></SENT>
<SENT sid="108" pm="."><plain>PF-04691502 was subsequently advanced into a phase I, open label, dose escalation study in subjects with solid tumours [84]. </plain></SENT>
</text></p><p><text><SENT sid="109" pm="."><plain>Fairhurst and Imblach have reported the discovery of a series of 4,5’-bisthiazoles with potent activity against the class I PI3Ks [85], notably p110α. </plain></SENT>
<SENT sid="110" pm="."><plain>Representative compounds include 64 (IC50, p110α, b, δ, γ = 14nM, 6.51µM, 764nM and 1.28µM respectively) and 65 (IC50, p110α, b, δ, γ = 14nM, 4.94µM, 531nM and 531nM respectively). </plain></SENT>
<SENT sid="111" pm="."><plain>In a separate report, Caravetti et al. outlined the discovery of a related series of compounds again displaying selectivity for p110α, including 66 (IC50, p110α, b, δ, γ = 14nM, 4.43µM, 971nM and 680nM respectively), and 67, which also showed greater potency compared with 66 for p110δ(IC50, p110α, β, δ, γ = 8nM, 1.21µM, 77nM and 1.09µM respectively) [86]. </plain></SENT>
</text></p><p><text><SENT sid="112" pm="."><plain>Kim et al. have described the discovery of fluorescent xanthine-based PI3K inhibitors with potent activity in T47D breast cancer cells. </plain></SENT>
<SENT sid="113" pm="."><plain>The principal biochemical activity of a representative compound disclosed in this report, 68,was p110α (IC50 = 150nM) [87]. </plain></SENT>
</text></p><p><text><SENT sid="114" pm="."><plain>Cheng and colleagues at Pfizer have reported the development of imidazo1,5naphthyridines with p110α and mTOR modulatory activity, and anti-tumour potency. </plain></SENT>
<SENT sid="115" pm="."><plain>One representative example is compound 69, which was amongst the most active dual-inhibitors disclosed (Ki, p110α = 167pM; mTOR = 232pM) [88]. </plain></SENT>
</text></p><p><text><SENT sid="116" pm="."><plain>Researchers at S*Bio have disclosed the discovery of a class of triazine-based inhibitors with p110α/mTOR dual activity, exemplified by 70 (IC50 &lt; 1µM) [89], and have, in a separate report, outlined the development of a series of purine derivatives with similar biochemical potencies, an example of which is 71 [90]. </plain></SENT>
</text></p><p><text><SENT sid="117" pm="."><plain>Morales et al. at Semafore have developed a class of small molecule anti-tumour agents with class I PI3K and mTOR activity, exemplified by the 7H-thieno[3,2-b]pyran-7-one, 72 [91]. </plain></SENT>
<SENT sid="118" pm="."><plain>This compound exhibited dual class IA/mTOR activity (IC50, p110α, b, δ, γ = 297nM, 378nM, 784nM and 1.57µM respectively; IC50, mTOR = 610nM). </plain></SENT>
</text></p><p><text><SENT sid="119" pm="."><plain>Staben et al. have reported on the characterization of the p110α inhibitors 73 and 74, which have respective IC50s of 162nM and 6.8nM, and which display potent pharmacodynamic biomarker modulatory activity in vitro, notablyeffects onphosphorylation of AKT, PRAS40 and RPS6, in PC3 prostate cancer cells [92]. </plain></SENT>
</text></p><p><text><SENT sid="120" pm="."><plain>Finally, Large et al. have reported the in vitro biochemical and cellular activities of a series of trisubstituted pyrimidines, exemplified by 75 [93]. This compound displayed potent activity against p110α (IC50 = 62nM), and inhibited the proliferation of IGROV-1 ovarian cancer cells with a GI50 of 370nM; the compound also displayed potent down-regulation of phospho-AKT in the same cell line. </plain></SENT>
</text></p></sec></sec><sec><label>3.2</label><title><text><SENT sid="121" pm="."><plain>Novel Inhibitors of p110β, p110δ and p110γ </plain></SENT>
</text></title><p><text><SENT sid="122" pm="."><plain>Fjellström et al. at AstraZeneca have demonstrated that (-)2-[1-(7-methyl-2-(morpholin-4-yl)4-oxo-4H-pyrido 1,2-a]pyrimidin-9-yl)ethylaminobenzoic acid, 76, displayed potent inhibition of p110β (IC50 = 21nM), with between 4- and 50-fold selectivity over the other PI3K isoforms [94]. </plain></SENT>
<SENT sid="123" pm="."><plain>In a separate report, Henteman and co-workers at Bayer have reported the discovery of sulfone substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives, exemplified by 77, with IC50 values against p110γ of less than 100nM [95]. </plain></SENT>
</text></p><p><text><SENT sid="124" pm="."><plain>Ramsden and co-workers at Cellzome have outlined the production of a targeted array of 2-aminoimidazo[1,2-b]pyridazine analogues with PI3K activity, and with potential in the treatment or prophylaxis of immunological, inflammatory, autoimmune or allergic disorders [96]. </plain></SENT>
<SENT sid="125" pm="."><plain>The most active compound, 78, displayed high potency against p110γ (IC50 &lt; 0.2µM) and 2-50 fold selectivity against the other PI3K isoforms. </plain></SENT>
<SENT sid="126" pm="."><plain>The same group has also outlined the discovery of 7-substituted aminotriazoles, exemplified by 79 [97], and urea triazolo[1,5-a]pyridine derivatives, exemplified by 80 [98], both of which display selectivity for p110γ with IC50 values of less than 100nM. </plain></SENT>
</text></p><p><text><SENT sid="127" pm="."><plain>Ren and co-workers at Intellikine have reported the synthesis of a library based on a pyrazolopyrimidine core possessing a benzothiazole moiety. </plain></SENT>
<SENT sid="128" pm="."><plain>These compounds were seen to display activity against the class I PI3Ks and mTOR, with compound 81 having an IC50 of less than 50nM against p110δ and p110γand mTOR, through with selectivity over p110β [99]. </plain></SENT>
<SENT sid="129" pm="."><plain>In a separate report, the same group outlined the synthesis of a series of pyrazolopyrimidines which exhibited activity against one or all PI3K isoforms [100]. </plain></SENT>
<SENT sid="130" pm="."><plain>Compound 82 was reported to have an IC50 of 100nM or less against p110δand p110γ whilst having at least 100-fold selectivity against the other two class I isoforms. </plain></SENT>
</text></p><p><text><SENT sid="131" pm="."><plain>Swinnen and co-workers at Merck-Serono have, in two separate reports, outlined the synthesis of libraries of small molecules based upon a [6,5]-heteroaromatic bicyclic core, with selective activity against p110γ, exemplified by 83 [101] and 84 [102]. </plain></SENT>
<SENT sid="132" pm="."><plain>In a further disclosure, Pomel and colleagues at Merck-Serono reported the production of a library based on 4-morpholino-pyrido3,2-dpyrimidines, which also displayed preferential activity for p110γ; one example, 85, was reported to have an IC50 of 220nM [103]. </plain></SENT>
</text></p><p><text><SENT sid="133" pm="."><plain>Researchers at Vertex have reported the development of a series of small molecule heterocycles, exemplified by 86, which target p110γ [104], and which displayed in vivo disease arrest in preclinical models of experimential autoimmune encephalomyclitis (EAE). </plain></SENT>
</text></p><p><text><SENT sid="134" pm="."><plain>Finally, Bruce et al. at Novartis have disclosed the development of a new class of small molecules with p110γ activity for use in the treatment of inflammatory and allergic diseases, an example of which is 87 (IC50 = 12nM) [105]. </plain></SENT>
</text></p></sec></sec><sec><label>4</label><title><text><SENT sid="135" pm="."><plain>TRANSLATION TO THE CLINIC: MOLECULAR BIOMARKERS </plain></SENT>
</text></title><p><text><SENT sid="136" pm="."><plain>The small molecule inhibitors of the PI3K enzymes described in this review are expected to impact several disease areas, particularly oncology. </plain></SENT>
<SENT sid="137" pm="."><plain>Key to the translation of targeted therapeutics into the clinic, including PI3K inhibitors described here, is the identification and application of a number of types of biomarker [3]. </plain></SENT>
<SENT sid="138" pm="."><plain>These range from proof-of-mechanism markers, that can be used to ascertain whether the targeted agent has inhibited the activity of the target and cognate pathway, to prognostic or predictive markers that can be employed to select (or at least enrich) patient populations that are most likely to respond or to determine response to treatment. </plain></SENT>
</text></p><p><text><SENT sid="139" pm="."><plain>Proof-of-mechanism biomarkers are particularly useful in early clinical studies to confirm target and pathway modulation and to define the pharmacodynamic relationship to dose, toxicity and potential response in the Pharmacological Audit Trail [108]. </plain></SENT>
<SENT sid="140" pm="."><plain>Biomarkers that have prognostic value, an ability to estimate a given patient’s outcome regardless of the nature of treatment, or predictive value, an ability to estimate the efficacy or the toxicity of an individual patient to a given treatment, allow clinicians to deliver the most appropriate drugs to selected patients and to spare patients unnecessary treatment where they would not benefit from it. </plain></SENT>
<SENT sid="141" pm="."><plain>It is important to note that nearly half of all new oncology drugs approved by the FDA since the launch of trastuzamab have some form of patient selection biomarker incorporated [109]. These biomarkers primarily focus on target biomarkers in tumours that predict patient response, although, more recently, tumour biomarkers of resistance have also been employed, as with mutant KRAS in EGFR-directed therapies. </plain></SENT>
<SENT sid="142" pm="."><plain>However, although we have made great progress in understanding the complex genetic alterations that underlie human cancer, and there are now several leading examples of molecularly targeted drugs that have exemplified using companion molecular diagnostic assays for patient stratification, it has often proven difficult to identify precisely which molecularly-targeted therapeutics would benefit which particular patients [108].  </plain></SENT>
</text></p><p><text><SENT sid="143" pm="."><plain>Significant progress has been made in identifying the most responsive tumour types and the underlying cellular pathways and molecular features determining response to PI3K inhibitors, in addition to pharmacodynamic biomarkers. </plain></SENT>
<SENT sid="144" pm="."><plain>However, it is clear that the situation is not simple, and that the choice of predictive biomarkers may well depend on the biology and genetics of the tumour type as well as the isoform selectivity profile of the agent concerned. </plain></SENT>
<SENT sid="145" pm="."><plain>To date several biomarkers potentially predicting tumour sensitivity have been investigated in preclinical and clinical settings, but none has yet been found to have a clearly defined, clinically qualified role for use in patients and thus more research is required. </plain></SENT>
<SENT sid="146" pm="."><plain>On the other hand, the emerging data show considerable promise and enrichment biomarkers are already in use in early trials of PI3K inhibitors in cancer patients. </plain></SENT>
</text></p><sec><label>4.1</label><title><text><SENT sid="147" pm="."><plain>Biomarkers of Mechanism of Action in the Discovery and Development of PI3K Inhibitors </plain></SENT>
</text></title><p><text><SENT sid="148" pm="."><plain>Despite the scientific and technical challenges of identifying a biomarker which specifically and robustly gives a measure of PI3K pathway inhibition, excellent progress has been made and a number of biomarkers are now being used for preclinical and clinical work. </plain></SENT>
<SENT sid="149" pm="."><plain>The PI3K pathway is a protein kinase cascade activated following the production of PIP3 in the plasma membrane, and this pathway has many nodes and branches, such that there are numerous phospho-proteins that could be potential biomarkers of PI3K inhibition. </plain></SENT>
<SENT sid="150" pm="."><plain>Quantification of a biomarker close to the point of PI3K inhibition would be the ideal option as this would be the most likely to provide a direct measure or PI3K inhibition. </plain></SENT>
<SENT sid="151" pm="."><plain>PIP3, the product of the reaction catalyzed by PI3K, would ideally fulfill this requirement for a biomarker of pathway activity. </plain></SENT>
<SENT sid="152" pm="."><plain>However, while measuring PIP3 using mass spectroscopy, thin layer chromatography or ELISA-based methods with PIP3 detector proteins is feasible in vitro, the challenges of measuring PIP3 (both stability and methodology) in samples from patients are generally thought to be very considerable at present. </plain></SENT>
<SENT sid="153" pm="."><plain>An alternative biomarker to PIP3 could be phosphorylation of a PDK1 substrate, since PDK1 is activated following recruitment to the plasma membrane by production of PIP3. </plain></SENT>
<SENT sid="154" pm="."><plain>AKT is directly phosphorylated at AKTTHR308 by PDK1 and this has been widely used as a measure of PI3K activity in in vitro tissue culture and in vivo tumour xenograft experiments [34]. </plain></SENT>
<SENT sid="155" pm="."><plain>However, the stability of phosphorylation of the AKTTHR308 site is generally thought not to be sufficiently robust for use in clinical studies. </plain></SENT>
<SENT sid="156" pm="."><plain>Other direct protein substrate targets of PDK1, such as SGKs, are yet to be explored as biomarkers of PI3K pathway inhibition. </plain></SENT>
<SENT sid="157" pm="."><plain>There has been considerable focus on phosphorylation of AKTSER473 and some downstream proteins as preclinical and clinical biomarkers of PI3K activity. </plain></SENT>
<SENT sid="158" pm="."><plain>The downstream markers of activity include PRAS40THR246, a substrate of AKT, and RPS6SER240/244 and 4EBP1THR37/46. </plain></SENT>
<SENT sid="159" pm="."><plain>However, none of these biomarkers are perfect as they are not entirely specific for PI3K activation/inhibition because their phosphorylation can be influenced directly or indirectly by mTOR kinase activity. </plain></SENT>
<SENT sid="160" pm="."><plain>In addition, they may be influenced by inputs from other pathways, for example RPS6 can be phosphorylated by p90S6K, a protein kinase regulated by other signalling cascades including MEK/ERK. </plain></SENT>
<SENT sid="161" pm="."><plain>Nevertheless they can play a useful research role. </plain></SENT>
</text></p><p><text><SENT sid="162" pm="."><plain>A number of studies have used unbiased screening strategies with the aim of identifying better and more specific biomarkers of PI3K inhibition for use in the development of PI3K inhibitors. </plain></SENT>
<SENT sid="163" pm="."><plain>Andersen and colleagues have employed immunoaffinity precipitation followed by mass spectrometry of protein extracts from cells that were treated with inhibitors of PDK1, AKT or PI3K/mTOR [110]. The aim of this study was to find specific biomarkers of PI3K pathway inhibition; it successfully led to the identification and quantification of 375 nonredundant phosphopeptides that were relevant to PI3K pathway signalling, and which contained AKT and PDK1 recognition motifs. </plain></SENT>
<SENT sid="164" pm="."><plain>Of these, seventy-one phosphopeptides were drug-modulated and 11 were reduced by all three inhibitors examined. </plain></SENT>
<SENT sid="165" pm="."><plain>An example was phosphorylation of the ribosomal protein RPS6 that was the most strongly inhibited by all 3 inhibitors and phosphorylation of PRAS40THR246 which was the most affected following AKT and PI3K/mTOR inhibition. </plain></SENT>
<SENT sid="166" pm="."><plain>PRASTHR246 was validated in lung and breast cancer cell lines and predicted sensitivity to an AKT inhibitor. </plain></SENT>
<SENT sid="167" pm="."><plain>Importantly, the phospho-PRASTHR246 epitope was more stable than the phospho-AKTSER473 epitope commonly used for identifying tumours with AKT pathway activation, suggesting that this biomarker might be more suitable for clinical evaluation of PI3K pathway inhibition. </plain></SENT>
<SENT sid="168" pm="."><plain>In particular it may be ideal for use in immunohistochemistry, which is often applied in clinical studies. </plain></SENT>
</text></p><p><text><SENT sid="169" pm="."><plain>The value of using ELISA-based methodology to measure quantitatively the phosphorylation of pathway proteins that are both proximal and distal to PI3K has been demonstrated with several inhibitors including GDC-0941, with potency declining at more distal points (34). </plain></SENT>
<SENT sid="170" pm="."><plain>Interestingly, although inhibition of substrate phosphorylation was valuable as a measure of PI3K target inhibition, the degree of inhibition measured by immune-assay did not predict sensitivity in this study. </plain></SENT>
</text></p><p><text><SENT sid="171" pm="."><plain>An alternative non-biased approach for pharmacodynamic biomarker discovery is to use microarray expression profiling to identify gene signatures specifically associated with PI3K inhibition. </plain></SENT>
<SENT sid="172" pm="."><plain>Guillard and colleagues profiled gene expression following treatment of human glioma cells with the class I PI3K/mTOR inhibitor PI-103 (18) and detected altered expression of genes encoding regulators of the cell cycle and cholesterol metabolism, together with genes modulated by insulin or IGF1 signalling, rapamycin treatment or nutrient starvation [111]. </plain></SENT>
<SENT sid="173" pm="."><plain>Expression profiling of ex vivo treated peripheral blood mononuclear cells (PBMCs) has also detected a gene signature associated with inhibition of PI3K inhibition; this was validated in microarray expression profiling of mice treated in vivo [112]. </plain></SENT>
<SENT sid="174" pm="."><plain>Further validation of selected cell surface proteins identified from the gene signature determined that the altered expression was specifically induced by PI3K inhibition and not induced by selected cytotoxic agents, MEK inhibitors or the mTORC1 inhibitor rapamycin in vitro or in vivo. </plain></SENT>
</text></p><p><text><SENT sid="175" pm="."><plain>Some of the biomarkers described herein have been reported as having been examined in early clinical studies of PI3K inhibitors. </plain></SENT>
<SENT sid="176" pm="."><plain>While it is preferable to look at the effects of PI3K inhibitors on pathway activation in tumours, and this has been done, it is sometimes difficult to access the tumour, or to obtain repeat biopsies. </plain></SENT>
<SENT sid="177" pm="."><plain>Therefore assessment of PI3K signalling in alternative surrogate normal tissues has also been considered. </plain></SENT>
<SENT sid="178" pm="."><plain>One option is the hair follicle, which is convenient for repeat sampling and importantly has high PI3K pathway basal activity. </plain></SENT>
<SENT sid="179" pm="."><plain>For example, in mouse studies the PI3K inhibitor PX-866 decreased phosphorylation AKTSER473 in both hair follicles and skin; also NVP-BEZ235 (10) has been reported to decrease RPS6SER240/244 and AKTSER473 phosphorylation in mouse skin [113,114]. </plain></SENT>
<SENT sid="180" pm="."><plain>Significantly, early clinical studies of XL765 have reported activity against phosphorylation of PRAS40THR246, 4EBP1THR37/46, RPS6SER240/244 and AKTSER473 in patient hair follicles [115], while another study has reported decreased RPS6SER240/244 in skin samples from patients treated with BMK120 [116]. PBMCs and platelet–rich plasma have also been considered as alternate tissues to determine PI3K pathway inhibition. </plain></SENT>
<SENT sid="181" pm="."><plain>Measurement of AKTSER473 phosphorylation in PBMC lysates has proved too variable to be useful; however, analysis of AKTSER473 levels in platelet-rich plasma has proved to be a successful alternative, and decreased AKTSER473 has been reported following treatment of patients with GDC-0941 and GDC-0980 [117-120]. Importantly, the extent of decreased AKTSER473 phosphorylation in platelet-rich plasma correlated with the dose of GDC-0941 and was concomitant with decreased RPS6SER240/244 phosphorylation in tumour biopsies. </plain></SENT>
</text></p><p><text><SENT sid="182" pm="."><plain>Demonstration of inhibition of PI3K signalling, generally using AKTSER473 or RPS6SER240/244 phosphorylation, has also been made in biopsies from solid tumours treated with XL147, GDC-0941, PX-866 and XL765 while a study with the p110δ specific inhibitor CAL-101 reported decreased AKTTHR308 in isolated lymphocytes from CLL patients [117-119,121-127]. </plain></SENT>
</text></p><p><text><SENT sid="183" pm="."><plain>In summarizing this section, various pharmacodynamic and proof-of-mechanism biomarkers have been developed which can be utilised to measure inhibition of the PI3K pathway in tumour biopsies and surrogate normal tissues. </plain></SENT>
<SENT sid="184" pm="."><plain>Use of these in early clinical trials is providing confidence that the pathway is inhibited by a given drug, and allows optimization of the dose and administration schedule (3). </plain></SENT>
<SENT sid="185" pm="."><plain>This forms an important part of the Pharmacological Audit Trail that is now important and widely used in the development of molecularly targeted drugs [108]. </plain></SENT>
</text></p></sec><sec><label>4.2</label><title><text><SENT sid="186" pm="."><plain>Selecting Patients Likely to Respond to PI3K Inhibitors </plain></SENT>
</text></title><p><text><SENT sid="187" pm="."><plain>As PI3K inhibitors progress through the early clinical safety studies and into trials focusing on clinical efficacy, selection of the patient population most likely to benefit from treatment becomes an important consideration [108]. A better understanding of drug sensitivity and resistance mechanisms is critical to the successful development and application of targeted cancer agents [128]. A good example is the inherent resistance of tumours to anti-EGFR antibody and small molecule therapies resulting from the presence of a KRAS mutation and the sensitivity of patients to the gefitinib and erlotinib EGFR inhibitors in non-small cell lung cancer patients with activating EGFR mutations. </plain></SENT>
<SENT sid="188" pm="."><plain>We have previously emphasised the importance of identifying predictive biomarkers to select patients that will be responsive or resistant to PI3K or PI3K/mTOR inhibitors [3]. </plain></SENT>
<SENT sid="189" pm="."><plain>An overview and update is provided here. </plain></SENT>
</text></p><p><text><SENT sid="190" pm="."><plain>Boyd and colleagues have used reverse phase protein arrays, to profile the phosphorylation status of 100 proteins in a panel of 30 breast cancer cell lines [129]. </plain></SENT>
<SENT sid="191" pm="."><plain>They found that sensitivity to the PI3K/mTOR inhibitor PI-103 was significantly correlated with elevated phosphorylation at key nodes in the PI3K/AKT/ mTOR pathway, including AKTTHR308, AKTSER473, PRASTHR246 and FKHRT24, suggesting that high levels of signalling through the pathway may be indicative of pathway addiction and be predictive of response to a targeted PI3K inhibitor. </plain></SENT>
<SENT sid="192" pm="."><plain>A study by Dan and colleagues came to a similar conclusion in a screen of a panel of 39 cell lines, in which they observed that cancer cell lines with high AKTSER473 were more sensitive to a range of PI3K inhibitors from different chemotypes [130]. However, there was no correlation observed between the level of AKT phosphorylation and PIK3CA mutation status [130,131]. </plain></SENT>
<SENT sid="193" pm="."><plain>In a separate study, there was no correlation seen between extent of pathway inhibition and sensitivity to PI3K inhibitors such as PI-103 and GDC-0941 [34]. </plain></SENT>
</text></p><p><text><SENT sid="194" pm="."><plain>A number of studies with different PI3K inhibitors have demonstrated that tumours with activating PIK3CA mutations or loss of PTEN expression are responsive to PI3K inhibition in vitro and in vivo [34]. </plain></SENT>
<SENT sid="195" pm="."><plain>Serra and colleagues demonstrated that NVP-BEZ235 had activity in tumours with PI3K activating mutations [114]. </plain></SENT>
<SENT sid="196" pm="."><plain>Two studies with the early prototype non-specific PI3K inhibitor LY294002 showed that cancer cell lines with PI3K mutations or, conversely, loss of PTEN expression showed increased sensitivity to PI3K inhibition [10,132]. </plain></SENT>
<SENT sid="197" pm="."><plain>More recent studies with NVP-BEZ235 or GDC-0941 have also shown that tumours with activating PIK3CA mutations exhibit increased sensitivity to PI3K inhibition [34,133,134]. </plain></SENT>
<SENT sid="198" pm="."><plain>These observations would suggest that a patient group with activating PIK3CA mutations or loss of PTEN expression would be the most suitable for treatment with PI3K inhibitors. </plain></SENT>
<SENT sid="199" pm="."><plain>However, the predictive value is not completely clear as, within these studies, there are tumours without PIK3CA mutations or loss of PTEN expression that are also sensitive to PI3K inhibition. </plain></SENT>
<SENT sid="200" pm="."><plain>Moreover, there are a number of in vitro or in vivo studies of cancer cell line panels that have failed to demonstrate the simple association of PIK3CA mutation or loss of PTEN expression with sensitivity to PI3K inhibitors [129,130,135-137]. Therefore, at the moment, an informed but pragmatic approach to targeting a patient population with PIK3CA mutations or PTEN expression loss with PI3K inhibitors is generally being used – one in which PIK3CA mutation and loss of PTEN expression is employed to enrich for patients that will tend to be more likely to respond to PI3K pathway inhibition. </plain></SENT>
<SENT sid="201" pm="."><plain>At the same time, we must also keep an open mind as it is clear that some tumours without these genetic abnormalities can be equally sensitive to PI3K inhibition, and recognize that the identification and validation of additional predictive biomarkers or signatures will be necessary. </plain></SENT>
<SENT sid="202" pm="."><plain>This research is ongoing. </plain></SENT>
</text></p><p><text><SENT sid="203" pm="."><plain>A confounding factor in determining the influence of activating mutations of the PI3K pathway on response to PI3K inhibitors may be the presence of other activated oncogenes. </plain></SENT>
<SENT sid="204" pm="."><plain>Mutations of KRAS are frequently co-incident with PIK3CA mutations (http://www.sanger.ac.uk/genetics/CGP/Census/). </plain></SENT>
<SENT sid="205" pm="."><plain>This may be related to the observation that KRAS and PIK3CA interact and, in mouse tumourigenesis models, PIK3CA has been shown to be required for KRAS-driven tumourigenesis through direct interaction [138]. Similarly, Engleman and colleagues have demonstrated in a mouse model of lung cancer that PI3K signalling is required for KRAS-driven tumourigenesis [139]. </plain></SENT>
<SENT sid="206" pm="."><plain>In that study, the mouse tumours driven by the PIK3CAH1047 mutation were responsive to NVP-BEZ235, but not rapamycin. </plain></SENT>
<SENT sid="207" pm="."><plain>In contrast, tumours driven by mutant KRAS were seen to be insensitive to NVP-BEZ235. </plain></SENT>
<SENT sid="208" pm="."><plain>In a similar vein, Ihle and colleagues noted that mutant PIK3CA and loss of PTEN activity were sufficient, but not necessary, as predictors of sensitivity to the anti-tumour activity of the PI3K inhibitor PX-866 in vivo in the presence of wild-type RAS, whereas mutant oncogenic RAS was a dominant determinant of resistance, even in tumours with coexisting mutations of PIK3CA [135]. In support of this, a study of a number of PI3K inhibitors from different chemotypes in a panel of 39 cancer cell lines in vitro and 24 in vivo tumourxenografts found a significant association of activating RAS or BRAF mutations with resistance to inhibition of the PI3K pathway [130]. Moreover, an additional study of 84 non-small cell lung cancer cell lines demonstrated reduced sensitivity in those with activating RAS mutations [137]. </plain></SENT>
</text></p><p><text><SENT sid="209" pm="."><plain>Additional potential factors associated with increased sensitivity to PI3K inhibition have also been identified. </plain></SENT>
<SENT sid="210" pm="."><plain>Sos and colleagues have shown that the presence of mutated or amplified receptor tyrosine kinase in non-small cell lung cancer cell lines correlated with increased sensitivity and apoptosis following treatment with PI3K inhibitors [137]. On the other hand, in the study of Faber and colleagues, inhibition of PI3K/mTOR signalling in non-small cell lung cancers with activating mutations of EGFR did not induce apoptosis, in contrast to HER2-amplified breast tumours in which sensitivity was seen [140]. Several further studies in breast cancer cells have also shown that the presence of amplified HER2 or the dual presence of PIK3CA mutation and HER2 amplification increases sensitivity to NVP-BEZ235 and GDC-0941, potentially through an increased cell death response [133,134]. In contrast to the HER2-amplified breast tumours, inhibition of PI3K/mTOR signalling non-small cell lung cancers with activating mutations of EGFR did not induce apoptosis. </plain></SENT>
</text></p><p><text><SENT sid="211" pm="."><plain>Importantly, even if an initial response to targeted therapies is successfully obtained, it is likely that the majority of tumours will at some later point acquire resistance to therapy, and become refractory to treatment [128]. This can either be a result of the acquisition of additional mutations or alternatively arise from the outgrowth of a resistant sub-clone already present in the tumour cell population. </plain></SENT>
<SENT sid="212" pm="."><plain>In the clinic this has been exemplified by tumours that acquire mutations of BCR-ABL, KIT, PDGFR and EGFR during treatment, where the mutated proteins are no longer susceptible to inhibition by the targeted agent, but retain enzymatic activity and the ability to promote cell growth and survival [141,142]. As PI3K inhibitors progress through the clinic it is possible that acquired resistance may also become a factor. </plain></SENT>
<SENT sid="213" pm="."><plain>Zunder and colleagues have addressed this issue using a S. cerevisiae screen against a structurally diverse panel of PI3K inhibitors [143]. </plain></SENT>
<SENT sid="214" pm="."><plain>They identified a potential hotspot for resistance mutations (PIK3CAI800) and a drug-sensitizing mutation (PIK3CAL814C). </plain></SENT>
<SENT sid="215" pm="."><plain>Resistance to small molecule inhibitors of protein kinases can occur as a result of mutations at one particular position in the active site. </plain></SENT>
<SENT sid="216" pm="."><plain>This mutated residue is known as the gatekeeper because it controls access to a large hydrophobic pocket in which most protein kinase inhibitors bind, and mutations of this type have now been reported for a number of protein kinases. </plain></SENT>
<SENT sid="217" pm="."><plain>In the case of EGFR, the gatekeeper mutated proteins retain receptor tyrosine kinase activity, but do not bind the EGFR inhibitor [141]. </plain></SENT>
<SENT sid="218" pm="."><plain>Importantly, the screen of Zunder et al. did not reveal resistance mutations at the gatekeeper residue and, in fact, these were unlikely to occur with PI3K inhibitors as introduction of gatekeeper mutations into PIK3CA resulted in a loss of enzymatic activity. </plain></SENT>
<SENT sid="219" pm="."><plain>Thus, the induction of resistance to PI3K inhibitors by this mechanism may be less likely than is the case for many protein kinase inhibitors. </plain></SENT>
</text></p><p><text><SENT sid="220" pm="."><plain>In summary, predictive biomarkers are now emerging that will help us to select patients that are more sensitive to PI3K inhibition. </plain></SENT>
<SENT sid="221" pm="."><plain>It is already clear that sensitivity and resistance is multifactorial and that the biomarkers already identified, including phosphorylation of PI3K pathway substrates, PIK3CA mutation, wild type KRAS and BRAF, loss of PTEN expression, HER2/ERBB2 amplification, and gene expression signatures, should be seen as useful enrichment biomarkers rather thantruly predictive biomarkers at this time [3,108]. There are likely to be confounding molecular factors affecting sensitivity and resistance in cancer cells and in addition the effects of PI3K inhibitors on processes such as angiogenesis and the tumour microenvironment are also likely to be important and contribute to therapeutic activity. </plain></SENT>
<SENT sid="222" pm="."><plain>The particular tumour type context and the particular isoform selectivity profile of the individual agent may well be important. </plain></SENT>
<SENT sid="223" pm="."><plain>Continuing research is needed to fully define, scientifically and technically validate, and clinically qualify the predictive biomarkers needed for eventual patient stratification in the event that PI3K inhibitors receive regulatory approval. </plain></SENT>
</text></p></sec></sec><sec><label>5</label><title><text><SENT sid="224" pm="."><plain>CLINICAL TRIALS IN CANCER </plain></SENT>
</text></title><p><text><SENT sid="225" pm="."><plain>A number of class I and dual class I/mTOR inhibitors have now entered clinical trial [144]. </plain></SENT>
<SENT sid="226" pm="."><plain>In this section we provide an update on the current status. </plain></SENT>
</text></p><sec><label>5.1</label><title><text><SENT sid="227" pm="."><plain>Pan-Class I Selective PI3K Inhibitors </plain></SENT>
</text></title><p><text><SENT sid="228" pm="."><plain>Pan-class I selective PI3K inhibitors have been shown to be well-tolerated and, in general, to induce minimal and reversible effects on serum glucose despite the established role of p110α in regulating insulin signalling. </plain></SENT>
<SENT sid="229" pm="."><plain>Other effects with ATP-competitive PI3K inhibitors include skin toxicity (rash and urticaria). </plain></SENT>
<SENT sid="230" pm="."><plain>Encouragingly, tumour responses stable disease and other signs of clinical efficacy have been reported in many clinical studies and in a variety of human cancers. </plain></SENT>
</text></p><p><text><SENT sid="231" pm="."><plain>Data on the clinical safety of the peptidic prodrug of LY204002, SF1126, in patients with advanced or metastatic tumours have been reported [145,146]. These studies demonstrated good tolerability and activity of the drug administered iv, which led to disease stabilization in patients with refractory tumours, including renal cell carcinoma and chronic lymphocytic leukaemia (CLL). </plain></SENT>
<SENT sid="232" pm="."><plain>Toxicities that were reported include nausea, vomiting, fatigue, urticaria and rash. </plain></SENT>
<SENT sid="233" pm="."><plain>No glucose or insulin changes have been reported. </plain></SENT>
<SENT sid="234" pm="."><plain>Evidence of pathway modulation has been claimed. </plain></SENT>
<SENT sid="235" pm="."><plain>Dose limiting toxicity has been reported at 1100mg/m2. </plain></SENT>
</text></p><p><text><SENT sid="236" pm="."><plain>XL147 was assessed in an open label, phase I dose escalation study that was carried out in patients with advanced solid tumours and lymphoma. </plain></SENT>
<SENT sid="237" pm="."><plain>Using a standard 3+3 design, patients with solid tumours received once daily XL147 on days 1-21 (21/7) or as a continuous daily dose in 28-day cycles. </plain></SENT>
<SENT sid="238" pm="."><plain>[121,122]. The 3+3 trial design is used for the majority of oncology phase I trials. </plain></SENT>
<SENT sid="239" pm="."><plain>According to this design, which is simple and straightforward to use, patients are treated in cohorts of 3; then, depending on the number of dose-limiting toxicities seen in the particular patient cohort, decisions are made on which dose to give the next cohort or whether to stop the trial. </plain></SENT>
<SENT sid="240" pm="."><plain>The maximum tolerated dose was 600 mg in both schedules. </plain></SENT>
<SENT sid="241" pm="."><plain>The most common drug-related toxicity that was seen was skin rash. </plain></SENT>
<SENT sid="242" pm="."><plain>Inhibition of PI3K and ERK pathway signalling was demonstrated in solid tumours, and prolonged stable disease has been observed in patients with cancers including non-Hodgkin’s lymphoma and non-small cell lung cancer. </plain></SENT>
<SENT sid="243" pm="."><plain>Two phase 1 combination studies have been reported with XL147. </plain></SENT>
<SENT sid="244" pm="."><plain>The combination with the EGFR inhibitor erlotinib was generally well tolerated at doses up to 400 mg XL147/150 mg erlotinib with no major pharmacokinetic interaction and resulted in clinical activity and robust simultaneous inhibition of PI3K and EGFR signalling [147,148]. The second combination study with paclitaxel and carboplatin showed that XL147 is well tolerated at doses up to 600 mg in combination with 175 mg/m2 and AUC 6 of paclitaxel and carboplatin respectively with no major pharmacokinetic interaction or emerging toxicities. </plain></SENT>
<SENT sid="245" pm="."><plain>Robust pharmacodynamic activity and tumour regression in heavily pre-treated patients have been observed in this study. </plain></SENT>
<SENT sid="246" pm="."><plain>Expansion cohorts will include patients with endometrial, ovarian and non-small cell lung cancer. </plain></SENT>
</text></p><p><text><SENT sid="247" pm="."><plain>Phase I clinical trials are currently being conducted with GDC-0941 [117,118]. Initial results have been reported from a phase I study using a 3+3 escalation design with a single dose of GDC-0941 and a 1-week washout, followed by GDC-0941 QD administered on a 3-week on, 1-week off schedule. </plain></SENT>
<SENT sid="248" pm="."><plain>A dose-proportional increase in drug exposure was observed from 15 to 450mg. </plain></SENT>
<SENT sid="249" pm="."><plain>Target modulation was reported with inhibition of AKTSER473 phosphorylation in platelet-rich plasma at doses above 80mg and a decrease in RPS6 immunostaining in tumours. </plain></SENT>
<SENT sid="250" pm="."><plain>In addition, objective decreases in metabolic activity as measured by positron emission tomography of fluorodeoxyglucose (I8FDG-PET) have been observed in patients’ tumours at doses above 80mg. </plain></SENT>
<SENT sid="251" pm="."><plain>GDC-0941 was generally well tolerated and exhibited signs of anti-tumour activity in a variety of cancers including breast, ovarian cancer, gastro-intestinal stromal tumour (GIST) and melanoma patients. </plain></SENT>
<SENT sid="252" pm="."><plain>Toxicities include fatigue, nausea, diarrhea and rash. </plain></SENT>
<SENT sid="253" pm="."><plain>Transient hyperglyceamia has been described. </plain></SENT>
<SENT sid="254" pm="."><plain>GDC-0941 is being evaluated in non-small cell lung cancer in combination with paclitaxel and carboplatin with or without bevacizumab. </plain></SENT>
<SENT sid="255" pm="."><plain>So far, these combinations appear to be well tolerated and no sign of pharmacokinetic interaction have been observed. </plain></SENT>
<SENT sid="256" pm="."><plain>Dose escalation is ongoing and clinical activity has been recorded [119]. A phase II study in breast cancer is recruiting </plain></SENT>
</text></p><p><text><SENT sid="257" pm="."><plain>In an initial phase 1 dose-escalation study evaluating an intermittent dosing schedule, PX-866 was well tolerated with diarrhoea and nausea observed as main toxicities. </plain></SENT>
<SENT sid="258" pm="."><plain>PX-866 was rapidly converted to an active metabolite (17-OH PX-866) which demonstrated improved potency relative to parent compound in kinase and cellular assays [123]. </plain></SENT>
<SENT sid="259" pm="."><plain>PX-866 was further evaluated using a continuous dosing schedule and has been well tolerated at 8 mg per day and associated with better disease control in heavily pre-treated patients than intermittent dosing. </plain></SENT>
<SENT sid="260" pm="."><plain>Clinical responses have been observed in pancreatic islet cell, colorectal, and prostate cancer. </plain></SENT>
<SENT sid="261" pm="."><plain>Predictive biomarkers are being explored. </plain></SENT>
</text></p><p><text><SENT sid="262" pm="."><plain>Patients were treated at 6 doses of BMK30 ranging from 12.5 mg to 150 mg [116]. The maximum tolerated dose was 100 mg. </plain></SENT>
<SENT sid="263" pm="."><plain>Treatment-related adverse events included rash, hyperglycaemia, diarrhoea, nausea, anorexia, pruritus, fatigue, mood alteration, malaise, vomiting, and mucositis. </plain></SENT>
<SENT sid="264" pm="."><plain>Preliminary pharmacokinetic analysis showed rapid absorption and low clearance from plasma leading to steady-state drug exposure estimated to be potentially efficacious based on preclinical data. </plain></SENT>
<SENT sid="265" pm="."><plain>Downregulation of pS6 in skin was seen in all patients at 100/150 mg. </plain></SENT>
<SENT sid="266" pm="."><plain>At 100 mg, 8 of 10 evaluable patients showed metabolic partial response by FDG-PET. </plain></SENT>
<SENT sid="267" pm="."><plain>Clinical responses were observed in triple negative breast cancer, colorectal cancer, angiosarcoma and lung cancer. </plain></SENT>
</text></p></sec><sec><label>5.2</label><title><text><SENT sid="268" pm="."><plain>Dual Pan-Class I PI3K/mTOR Inhibitors </plain></SENT>
</text></title><p><text><SENT sid="269" pm="."><plain>The safety profile and tolerability of the dual pan-PI3K/mTOR inhibitors generally appears to be similar to that of the pan-inhibitors. </plain></SENT>
<SENT sid="270" pm="."><plain>Several organizations are developing candidates with both profiles and it is currently unclear what the ideal PI3K family isoform selectivity profile or profiles in the clinic will be. </plain></SENT>
<SENT sid="271" pm="."><plain>Signs of clinical activity are also encouraging for the development of these agents. </plain></SENT>
</text></p><p><text><SENT sid="272" pm="."><plain>The first reports from clinical trials conducted in patients with solid tumours showed promising drug safety and tolerability for NVP-BEZ235 with signs of clinical activity in patients with tumours bearing PI3K pathway alterations [149]. Toxicities that were reported included nausea, vomiting, diarrhea, fatigue/asthenia, anemia, and anorexia; these effects were mild or moderate, manageable, and reversible upon treatment discontinuation. </plain></SENT>
<SENT sid="273" pm="."><plain>AUC and Cmax were found to increase non-proportionally with dose and were variable within and among patients. </plain></SENT>
<SENT sid="274" pm="."><plain>NVP-BEZ235 exhibited dose- and day-dependent PI3K inhibition as measured by elevation of plasma C-peptide levels. </plain></SENT>
<SENT sid="275" pm="."><plain>2 partial responses (1 Cowden syndrome patient, 1 breast cancer patient) and 16 measurable responses were observed. </plain></SENT>
<SENT sid="276" pm="."><plain>14 of 51 evaluable patients had stable disease for ≥4 months; tumours from 6 of these 14 patients carried dysregulation of the PI3K pathway. </plain></SENT>
<SENT sid="277" pm="."><plain>Four of the 14 (29%) patients with stable disease for ≥4 months had breast cancer. </plain></SENT>
<SENT sid="278" pm="."><plain>18 of 35 evaluable patients had detectable decreases of 18FDG uptake. </plain></SENT>
<SENT sid="279" pm="."><plain>An improved formulation of the compound will be used in future studies. </plain></SENT>
</text></p><p><text><SENT sid="280" pm="."><plain>XL765 was administered twice daily (BID) or daily (QD) for 28-day cycles with a standard 3+3 dose escalation design in patients with solid tumours and lymphoma. </plain></SENT>
<SENT sid="281" pm="."><plain>The most common related adverse events (&gt; 10% of patients) were observed to be nausea, diarrhoea, anorexia, elevated liver enzymes, skin disorders, and vomiting. </plain></SENT>
<SENT sid="282" pm="."><plain>Exposure was found to be increased with increasing doses on BID and QD schedules. </plain></SENT>
<SENT sid="283" pm="."><plain>Robust pharmacodynamic modulation of PI3K and ERK pathway signalling was evident both in tumours and surrogate tissues following dosing of XL765. </plain></SENT>
<SENT sid="284" pm="."><plain>For example, decreases in phosphorylation of AKTTHR308 (57-76%) or of 4EBP1 (62-80%), as well as ERK (53-80%), were observed in paired biopsies of various solid tumours from patients receiving 50 mg BID. </plain></SENT>
<SENT sid="285" pm="."><plain>Eleven patients have been reported to be on study for ≥ 16 weeks and seven patients on treatment for ≥ 24 weeks.The maximum tolerated dose for single-agent XL765 is reported as 50 mg BID. </plain></SENT>
<SENT sid="286" pm="."><plain>XL765 exhibited potent pharmacodynamic activity in solid tumours and surrogate tissues at generally well tolerated doses [126]. </plain></SENT>
<SENT sid="287" pm="."><plain>XL765 in combination with the DNA methylating agent temozolomide is well tolerated at doses up to 40 mg QD. </plain></SENT>
<SENT sid="288" pm="."><plain>There was no apparent pharmacokinetic interaction between XL765 and temozolamide. </plain></SENT>
<SENT sid="289" pm="."><plain>Maximum tolerated dose determinations for QD and BID schedules are ongoing. </plain></SENT>
<SENT sid="290" pm="."><plain>Signs of disease stabilisation have been observed. </plain></SENT>
<SENT sid="291" pm="."><plain>XL765 in combination with erlotinib is also generally well tolerated at daily doses up to 50 mg XL765/100 mg erlotinib with no apparent pharmacokinetic interaction, and results in robust inhibition of PI3K and EGFR signalling in skin and tumour tissue. </plain></SENT>
<SENT sid="292" pm="."><plain>The maximum tolerated dose for the combination has not yet been determined [124,125]. </plain></SENT>
</text></p><p><text><SENT sid="293" pm="."><plain>The phase I dose escalation study of GDC-0980 was carried out in patients with solid tumours or non-Hodgkin's lymphoma and used a 3+3 design [120].GDC-0980 was given on day 1, followed by 1week washout to investigate single-dose pharmacokinetic and pharmacodynamic biomarkers. </plain></SENT>
<SENT sid="294" pm="."><plain>The most frequently reported adverse events were nausea (25%), fatigue (50%), diarrhoea (42%), and flatulence (25%). </plain></SENT>
<SENT sid="295" pm="."><plain>GDC-0980 was found to be generally well tolerated up to 16 mg administered orally QD with potential signs of anti-tumour activity. </plain></SENT>
<SENT sid="296" pm="."><plain>Preliminary pharmacokinetic data suggest dose-proportional increases in Cmax and AUC. </plain></SENT>
<SENT sid="297" pm="."><plain>Initial pharmacodynamic biomarker data showed &gt;50% inhibition of phosphorylated AKTSER473 levels assayed in platelet-rich plasma after a single dose of 8 mg and higher of GDC-0980. </plain></SENT>
<SENT sid="298" pm="."><plain>Of potential interest, evidence of anti-tumour activity was observed in a mesothelioma patient previously treated with radiation and cisplatin. </plain></SENT>
<SENT sid="299" pm="."><plain>The recommended dose is yet to be established </plain></SENT>
</text></p><p><text><SENT sid="300" pm="."><plain>Two candidates from Pfizer are currently being developed, one for i.v. administration (PF-04691502), and one for oral dosing PF-05212384[150,151]. </plain></SENT>
<SENT sid="301" pm="."><plain>Both compounds are dual PI3K/mTOR inhibitors and show acceptable pharmacokinetic profiles after 3 dose escalations. </plain></SENT>
<SENT sid="302" pm="."><plain>So far no clinical activity has been reported. </plain></SENT>
<SENT sid="303" pm="."><plain>Pharmacodynamic biomarker assessment is being performed by measurement of glucose and insulin levels in blood. </plain></SENT>
<SENT sid="304" pm="."><plain>Nausea, fatigue, headache and hyperglycaemia have been the most frequently reported treatment-related adverse events so far. </plain></SENT>
<SENT sid="305" pm="."><plain>Dose escalation is ongoing for both compounds </plain></SENT>
</text></p></sec><sec><label>5.3</label><title><text><SENT sid="306" pm="."><plain>p110δ-Selective PI3K Inhibitors </plain></SENT>
</text></title><p><text><SENT sid="307" pm="."><plain>The potent p110δ-specific inhibitor CAL-101 exhibits 40- to 300-fold selectivity for that particular isoform, as compared to other PI3K enzymes and is undergoing Phase I clinical evaluation in relapsed or refractory haematological malignancies (CLL, acute myeloid leukaemia, multiple myeloma and non-Hodgkin’s lymphoma) [127]. The first interim reports from phase I trials with CAL-101 show promising drug activity and a lack of severe toxicity in haematological cancer patients. </plain></SENT>
<SENT sid="308" pm="."><plain>Plasma exposure was shown to increase with dose. </plain></SENT>
<SENT sid="309" pm="."><plain>AKTTHR308 as a marker of PI3K activation was measured in cells from a subset of chronic lymphocytic leukaemia patients with circulating lymphocytes and was observed to be reduced by &gt;90% following dosing, demonstrating target inhibition. </plain></SENT>
</text></p></sec></sec><SecTag type="DISCUSS,CONCL"><sec><label>6</label><title><text><SENT sid="310" pm="."><plain>SUMMARY AND FUTURE PERSPECTIVE </plain></SENT>
</text></title><p><text><SENT sid="311" pm="."><plain>As mentioned earlier in this review, the progression of PI3K inhibitors over the last twenty years or so has been remarkable. </plain></SENT>
<SENT sid="312" pm="."><plain>There are a number of interesting and important features that can be highlighted. </plain></SENT>
</text></p><p><text><SENT sid="313" pm="."><plain>First is the evolution from chemical tool compounds, like LY294002 1, Wortmannin 2 and PI-103 18 [152], to drugs that are now beginning to show pharmacodynamic evidence of target modulation and clear signs of therapeutic benefit to cancer patients [3,153]. </plain></SENT>
</text></p><p><text><SENT sid="314" pm="."><plain>Next to highlight is the impact of the crystal structures of p110 catalytic domains, facilitating the interpretation of isoform selectivity profiles and the prospective design of desired profiles [3,154-156]. In the landmark study by Knight et al. [106],common selectivity combinations were identified, as with agents that exhibit preferences for p110α/p110γ and p110β/δ (termed ‘pharmalogs’). </plain></SENT>
<SENT sid="315" pm="."><plain>Inhibitors of p110α often also inhibit the class IV isoforms DNA-PK and mTOR, as with PI-103, but it has been possible to remove the class IV inhibition from class I-selective inhibitors as in case of GDC-0941 3 compared to PI-103 [34]. </plain></SENT>
<SENT sid="316" pm="."><plain>The desirability of p110α/pan-class I isoform selectivity for cancer therapy is still being debated [3,34,107]. It is now clear that highly selective inhibitors of p110δ can be produced and that p110γ/δ inhibitors can also be obtained, for potential use in inflammation. </plain></SENT>
<SENT sid="317" pm="."><plain>Many variations on these core patterns exist. </plain></SENT>
<SENT sid="318" pm="."><plain>Although mouse models will help, it is likely that the preferred isoform selectivity profiles for medical use, as distinct from chemical tools, will only emerge following detailed clinical evaluation of multiple agents. </plain></SENT>
<SENT sid="319" pm="."><plain>For future drug design, the SAR rules for achieving selectivity are progressively being defined, facilitated by the increasing availability of crystal structures. </plain></SENT>
<SENT sid="320" pm="."><plain>In addition to the various isoform-targeted inhibitors developed to date, there is also significant emerging potential for p110β and dual p110β/δ inhibitors for the treatment of immune-inflammatory diseases and cancer [19, 12, 157-160] and also of p110γ inhibitors in the latter therapeutic area [161]. </plain></SENT>
</text></p><p><text><SENT sid="321" pm="."><plain>Also important has been the use of proof of mechanism pharmacodynamic biomarkers to demonstrate target and pathway modulation in both the preclinical discovery phase and the early clinical development of PI3K inhibitors. </plain></SENT>
<SENT sid="322" pm="."><plain>This is critical in the implementation of the Pharmacological Audit Trail [108], enabling rational optimization of dose and schedule of administration as well as go/no go decision-making. </plain></SENT>
<SENT sid="323" pm="."><plain>In addition, progress has also been made on the identification of potential predictive biomarkers for the identification of patients that are most likely to respond to PI3K inhibitors. </plain></SENT>
<SENT sid="324" pm="."><plain>These include PIK3CA mutation, PTEN expression loss, HER2/ERBB2 amplification/overexpression, wild type KRAS and gene expression signatures. </plain></SENT>
</text></p><p><text><SENT sid="325" pm="."><plain>Finally to be highlighted is the emerging picture from the clinic of PI3K inhibitors as generally well tolerated agents that are already beginning to show evidence of single agent therapeutic activity in early clinical trials in cancer patients. </plain></SENT>
<SENT sid="326" pm="."><plain>Concerns about potential effects on glucose metabolism appear to have been alleviated, with only mild effects being seen, at least with the doses and schedules used to date. </plain></SENT>
</text></p><p><text><SENT sid="327" pm="?"><plain>What then are the key issues facing the preclinical discovery and clinical development of class I PI3K and class I/class IV inhibitors for cancer treatment? </plain></SENT>
</text></p><p><text><SENT sid="328" pm="."><plain>Identifying optimal isoform selectivity profiles has already been discussed and is ongoing. </plain></SENT>
<SENT sid="329" pm="."><plain>Related to this point, more work needs to be done to identify the best predictive markers of sensitivity for drugs with different selectivity profiles. </plain></SENT>
<SENT sid="330" pm="."><plain>In addition, further research on biomarkers of resistance, both intrinsic and acquired, is also essential. </plain></SENT>
<SENT sid="331" pm="."><plain>At the moment the available biomarkers are probably best described as enrichment biomarkers – for use in enriching early clinical trials for patients with malignancies with molecular characteristics (PI3K pathway addiction) that make them more likely to respond. </plain></SENT>
<SENT sid="332" pm="."><plain>Much more work needs to be done to validate and clinically qualify biomarkers that may be truly predictive. </plain></SENT>
<SENT sid="333" pm="."><plain>It needs to be remembered that, especially since PI3K inhibitors can have effects on tumour angiogenesis and tumour microenvironmental interactions, there may not be a single biomarker of sensitivity but rather a group of these or a predictive molecular signature. </plain></SENT>
<SENT sid="334" pm="."><plain>Studies in preclinical systems, including large molecularly characterised cancer cell panels and human tumour xenografts, together with genetically engineered mouse models, will be useful for this. </plain></SENT>
<SENT sid="335" pm="."><plain>However, it is likely that many of the answers will be worked out by molecular profiling, including cancer genome sequencing, of clinical tumour material and the correlation of such data with therapeutic response and outcome. </plain></SENT>
</text></p><p><text><SENT sid="336" pm="."><plain>Many PI3K inhibitors are now progressing through phase II single agent efficacy studies and the results are eagerly awaited by the oncology community. </plain></SENT>
<SENT sid="337" pm="."><plain>Combination studies are also underway. </plain></SENT>
<SENT sid="338" pm="."><plain>Because of the number of potential combinations, it may take some time to identify optimal combinations and both preclinical and clinical studies will be important for this. </plain></SENT>
<SENT sid="339" pm="."><plain>Some rationally based combinations, for example with MEK inhibitors, have obvious mechanistic appeal and these are being prioritized [3]. </plain></SENT>
</text></p><p><text><SENT sid="340" pm="."><plain>In addition to cancer indications, there is exciting potential for PI3K inhibitors in other therapeutic contexts, particularly immune inflammation and cardiovascular disease. </plain></SENT>
</text></p><p><text><SENT sid="341" pm="."><plain>It has been a fascinating journey so far with PI3K inhibitors. </plain></SENT>
<SENT sid="342" pm="."><plain>With the range of agents now coming through that have distinct and attractive profiles, in the next few months and years there should increasing opportunities to reveal further evidence of clinical utility. </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><title>ACKNOWLEDGEMENTS</title><p><text4fund><text><SENT sid="343" pm="."><plain>We thank our many colleagues and collaborators for valuable discussions. </plain></SENT>
<SENT sid="344" pm="."><plain>We also thank Dr Rob van Montfort for assistance with Fig. </plain></SENT>
<SENT sid="345" pm="."><plain>(1). </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="COMP_INT"><sec><title>CONFLICT OF INTEREST</title><p>Paul Workman, Paul Clarke and Florence Raynaud are employees of the Institute of Cancer Research, which has a commercial interest in the development of PI3K inhibitors, including GDC-941, and operates a rewards-to-inventors scheme. They have previously been involved in a commercial collaboration with Yamanouchi (now Astellas Pharma) and with Piramed Pharma and intellectual property arising from the program has been licensed to Genentech. Paul Workman was a founder of, consultant to, and Scientific Advisory Board member of Piramed Pharma (acquired by Roche); has been a founder of, consultant to and Scientific Advisory Board and Main Board member of Chroma Therapeutics; is on the Medical Advisory Board of WILEX; and was formerly an employee of AstraZeneca. Florence Raynaud is a consultant for ELARA Pharmaceuticals. Stephen Shuttleworth was previously an employee of Piramed Pharma. Stephen Shuttleworth, Franck Silva, Alexander Cecil, Cyrille Tomassi, Thomas Hill are employees of Karus Therapeutics Limited.</p></sec></SecTag><SecTag type="REF"><ref-list><title>REFERENCES</title><ref id="R1"><text><SENT sid="346" pm="."><plain>1VivancoISawyersCLThe phosphatidylinositol 3-kinase AKT pathway in human cancerNature Rev. </plain></SENT>
<SENT sid="347" pm="."><plain>Cancer2002248950112094235 </plain></SENT>
</text></ref><ref id="R2"><text><SENT sid="348" pm="."><plain>2DreesBEMillsGBRommelCPrestwichGDTherapeutic potential of phosphoinositide 3-kinase inhibitorsExp. </plain></SENT>
<SENT sid="349" pm="."><plain>Opin. </plain></SENT>
<SENT sid="350" pm="."><plain>Ther. </plain></SENT>
<SENT sid="351" pm="."><plain>Patents200414703732 </plain></SENT>
</text></ref><ref id="R3"><text><SENT sid="352" pm="."><plain>3WorkmanPClarkePARaynaudFIvan MontfortRLDrugging the PI3 kinome: from chemical tools to drugs in the clinicCancer Res2010702146215720179189 </plain></SENT>
</text></ref><ref id="R4"><text><SENT sid="353" pm="."><plain>4ShuttleworthSSilvaFTomassiCCecilAHillTRogersHTownsendPLawtonWitty Progress In Medicinal Chemistry2009Vol 48Elsevier Science B81129 </plain></SENT>
</text></ref><ref id="R5"><text><SENT sid="354" pm="."><plain>5BjornstiMAHoughtonPJThe TOR Pathway: A target for cancer therapyNat. </plain></SENT>
<SENT sid="355" pm="."><plain>Rev. </plain></SENT>
<SENT sid="356" pm="."><plain>Cancer2004433534815122205 </plain></SENT>
</text></ref><ref id="R6"><text><SENT sid="357" pm="."><plain>6GuertinDASabatiniDMDefining the role of mTOR in cancerCancer Cell20071292217613433 </plain></SENT>
</text></ref><ref id="R7"><text><SENT sid="358" pm="?"><plain>7SteinRCWaterfieldMDPI3-kinase inhibition: a target for drug development? </plain></SENT>
<SENT sid="359" pm="."><plain>MolMed. </plain></SENT>
<SENT sid="360" pm="."><plain>Today20006347358 </plain></SENT>
</text></ref><ref id="R8"><text><SENT sid="361" pm="."><plain>8IhleNTPowisGTake your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapyMol. </plain></SENT>
<SENT sid="362" pm="."><plain>Cancer Ther200981919139107 </plain></SENT>
</text></ref><ref id="R9"><text><SENT sid="363" pm="."><plain>9ChalhoubNBakerSJPTEN and the PI3-Kinase Pathway in CancerAnn. </plain></SENT>
<SENT sid="364" pm="."><plain>Rev. </plain></SENT>
<SENT sid="365" pm="."><plain>Pathol. </plain></SENT>
<SENT sid="366" pm="."><plain>Mech. </plain></SENT>
<SENT sid="367" pm="."><plain>Disease20094127150 </plain></SENT>
</text></ref><ref id="R10"><text><SENT sid="368" pm="."><plain>10SamuelsYDiaz L.AJrSchmidt-KittlerOCumminsJMDelongLCheongIRagoCHusoDLLengauerCKinzlerKWVogelsteinBVelculescuVEMutant PIK3CA promotes cell growth and invasion of human cancer cellsCancer Cell2005756157315950905 </plain></SENT>
</text></ref><ref id="R11"><text><SENT sid="369" pm="."><plain>11VogtPGymnopolousMHartJRPI 3-kinase and cancer: changing accentsCurr. </plain></SENT>
<SENT sid="370" pm="."><plain>Opin. </plain></SENT>
<SENT sid="371" pm="."><plain>Genetics and Dev20091916 </plain></SENT>
</text></ref><ref id="R12"><text><SENT sid="372" pm="."><plain>12WeeSWiederschainDMairaSMLooAMillerCDeBeaumontRStegmeierFYaoYMLengauerCPTEN-deficient cancers depend on PIK3CBProc. </plain></SENT>
<SENT sid="373" pm="."><plain>Natl. </plain></SENT>
<SENT sid="374" pm="."><plain>Acad. </plain></SENT>
<SENT sid="375" pm="."><plain>Sci. </plain></SENT>
<SENT sid="376" pm="."><plain>USA2008105130571306218755892 </plain></SENT>
</text></ref><ref id="R13"><text><SENT sid="377" pm="."><plain>13JiaSRobertsTMZhaoJJShould individual PI3 kinase isoforms be targeted in cancer?Curr. </plain></SENT>
<SENT sid="378" pm="."><plain>Opin. </plain></SENT>
<SENT sid="379" pm="."><plain>Cell. </plain></SENT>
<SENT sid="380" pm="."><plain>Biol20092119920819200708 </plain></SENT>
</text></ref><ref id="R14"><text><SENT sid="381" pm="."><plain>14BillottetCGrandageVLGaleREQuattropaniARommelCVanhaesebroeckBKhwajaAA selective inhibitor of the p110δ isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16Oncogene2006256648665916702948 </plain></SENT>
</text></ref><ref id="R15"><text><SENT sid="382" pm="."><plain>15Cornillet-LefebvrePCuccuiniWBardetVTamburiniJGillotLIfrahNNguyenPDreyfusFMayeuxPLacombeCBouscaryDConstitutive phosphoinositide 3-kinase activation in acute myeloid leukemia is not due to p110δ mutationsLeukemia20062037437616341041 </plain></SENT>
</text></ref><ref id="R16"><text><SENT sid="383" pm="."><plain>16JacksonSPSchoenwaelderSMGoncalvesINesbittWSYapCLWrightCEKencheVAndersonKEDopheideSMYuanYSturgeonSAPrabaharanHThompsonPESmithGDShepherdPRDanieleNKulkarniSAbbottBSaylikDJonesCLuLGiulianoSHughanSCAngusJARobertsonADSalemHHPI 3-kinase p110ß: a new target for antithrombotic therapyNature Med20051150751415834429 </plain></SENT>
</text></ref><ref id="R17"><text><SENT sid="384" pm="."><plain>17UtsugiMDobashiKOnoAIshizukaTMatsuzakiSHisadaTShimizuYKawataTAokiHKamideYMoriMPI3K p110ß Positively Regulates Lipopolysaccharide-Induced IL-12 Production in human macrophages and dendritic cells and JNK1 plays a novel roleJ. </plain></SENT>
<SENT sid="385" pm="."><plain>Immunol20091825225523119380768 </plain></SENT>
</text></ref><ref id="R18"><text><SENT sid="386" pm="."><plain>18WindmillerDABackerJMDistinct phosphoinositide 3-kinases mediate mast cell degranulation in response to G-protein-coupled versus FcepsilonRI receptorsJ. </plain></SENT>
<SENT sid="387" pm="."><plain>Biol. </plain></SENT>
<SENT sid="388" pm="."><plain>Chem2003278118741187812529321 </plain></SENT>
</text></ref><ref id="R19"><text><SENT sid="389" pm="."><plain>19BoyleKBGyoriDSindrilaruAScharffetter-KochanekKTaylorPRMócsaiAStephensLRHawkinsPTClass IA Phosphoinositide 3-Kinase ? amd ??Regulated Neutrophil Oxidase Activation in Response to Aspergillus fumigatus HyphaeJ. </plain></SENT>
<SENT sid="390" pm="."><plain>Immunol201118652978298921257963 </plain></SENT>
</text></ref><ref id="R20"><text><SENT sid="391" pm="?"><plain>20RommelCCampsMJiHPI3Kd and PI3K?: partners in crime in inflammation in rheumatoid arthritis and beyond? </plain></SENT>
<SENT sid="392" pm="."><plain>Nature RevImmunol20077191201 </plain></SENT>
</text></ref><ref id="R21"><text><SENT sid="393" pm="."><plain>21WalkerEHPerisicORiedCStephensLWilliamsRLStructural insights into phosphoinositide 3-kinase catalysis and signallingNature (London)199940231332010580505 </plain></SENT>
</text></ref><ref id="R22"><text><SENT sid="394" pm="."><plain>22AliKBilancioAThomasMPearceWGilfillanAMTkaczykCKuehnNGrayAGiddingsJPeskettEFoxRBruceIWalkerCSawyerCOkkenhaugKFinanPand VanhaesebroeckBEssential role for the p110δ phosphoinositide 3-kinase in the allergic responseNature (London)20044311007101115496927 </plain></SENT>
</text></ref><ref id="R23"><text><SENT sid="395" pm="."><plain>23RückleSchwarzMKRommelCPI3K? inhibition: towards an aspirin of the 21st century?Nature Rev. </plain></SENT>
<SENT sid="396" pm="."><plain>Drug Discov2006590391817080027 </plain></SENT>
</text></ref><ref id="R24"><text><SENT sid="397" pm="."><plain>24ParkSJLeeKSKimSRMinKHMoonHLeeMHChungCRHanHJPuriKDLeeYCPhosphoinositide 3-kinase δ inhibitor suppresses IL-17 expression in a murine asthma modelEur. </plain></SENT>
<SENT sid="398" pm="."><plain>Respir. </plain></SENT>
<SENT sid="399" pm="."><plain>J201036e-pub ahead of print </plain></SENT>
</text></ref><ref id="R25"><text><SENT sid="400" pm="."><plain>25BerndtAMillerSWilliamsOLeDDHousemanBTPacoldJIGorrecFHonWCLiuYRommelCGaillardPRückleTSchwarzMKShokatKMShawJPWilliamsRLThe p110δ structure: mechanisms for selectivity and potency of new PI(3)K inhibitorsNature Chem. </plain></SENT>
<SENT sid="401" pm="."><plain>Biol2010611712420081827 </plain></SENT>
</text></ref><ref id="R26"><text><SENT sid="402" pm="."><plain>26ShuttleworthSSilvaFTomassiCCecilAHillTRogersHTownsendPLawtonWittyProgress In Medicinal Chemistry, Elsevier Science B2011Vol 50Elsevier Science B. </plain></SENT>
<SENT sid="403" pm="."><plain>V109133 </plain></SENT>
</text></ref><ref id="R27"><text><SENT sid="404" pm="."><plain>27BrazeltonTRMorrisREMolecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomideCurr. </plain></SENT>
<SENT sid="405" pm="."><plain>Opin. </plain></SENT>
<SENT sid="406" pm="."><plain>Immunol199687107208902398 </plain></SENT>
</text></ref><ref id="R28"><text><SENT sid="407" pm="."><plain>28VlahosCJMatterWFHuiKYBrownRFA specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)J. </plain></SENT>
<SENT sid="408" pm="."><plain>Biol. </plain></SENT>
<SENT sid="409" pm="."><plain>Chem1994269524152488106507 </plain></SENT>
</text></ref><ref id="R29"><text><SENT sid="410" pm="."><plain>29KongDYamoriTPhosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapyCancer Sci2008991734174018616528 </plain></SENT>
</text></ref><ref id="R30"><text><SENT sid="411" pm="."><plain>30MairaSMStaufferFSchnellCGarcía-EcheverriaCPI3K inhibitors for cancer treatment: where do we stand?Biochem. </plain></SENT>
<SENT sid="412" pm="."><plain>Soc. </plain></SENT>
<SENT sid="413" pm="."><plain>Trans20093726527219143644 </plain></SENT>
</text></ref><ref id="R31"><text><SENT sid="414" pm="."><plain>31IhleNTPowisGInhibitors of phosphatidylinositol-3-kinase in cancer therapyMolecular Asp. </plain></SENT>
<SENT sid="415" pm="."><plain>Med20103113544 </plain></SENT>
</text></ref><ref id="R32"><text><SENT sid="416" pm="."><plain>32ItoKCaramoriGAdcockIMTherapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory diseaseJ. </plain></SENT>
<SENT sid="417" pm="."><plain>Pharmacol. </plain></SENT>
<SENT sid="418" pm="."><plain>Exp. </plain></SENT>
<SENT sid="419" pm="."><plain>Ther20073211817021257 </plain></SENT>
</text></ref><ref id="R33"><text><SENT sid="420" pm="."><plain>33FolkesAJAhmadiKAldertonWKAlixSBakerSJBoxGChuckowreeISClarkePADepledgePEcclesSAFriedmanLSHayesAHancoxTCKugendradasALensunLMoorePOliveroAGPangJPatelSPergl-WilsonGHRaynaudFIRobsonASaghirNSalphatiLSohalSUltschMHValentiMWallweberHJAWanNCWiesmannCWorkmanPZhyvoloupAZvelebilMJShuttleworthSJThe identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancerJ. </plain></SENT>
<SENT sid="421" pm="."><plain>Med. </plain></SENT>
<SENT sid="422" pm="."><plain>Chem2008515522553218754654 </plain></SENT>
</text></ref><ref id="R34"><text><SENT sid="423" pm="."><plain>34RaynaudFIEcclesSAPatelSAlixSBoxGChuckowreeIFolkesAGowanSDe Haven-BrandonADi StefanoFHayesAHenleyATLensunLPergl-WilsonGRobsonASaghirNZhyvoloupAMcDonaldESheldrakePShuttleworthSValentiMWanNCClarkePAWorkmanPBiological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941Mol. </plain></SENT>
<SENT sid="424" pm="."><plain>Can. </plain></SENT>
<SENT sid="425" pm="."><plain>Ther2009817251738 </plain></SENT>
</text></ref><ref id="R35"><text><SENT sid="426" pm="."><plain>35GaleSCroasdellG28th Annual JPMorgan Healthcare Conference--Exelixis and Nektar TherapeuticsiDrugs20101313914120191424 </plain></SENT>
</text></ref><ref id="R36"><text><SENT sid="427" pm="."><plain>36KnightSDAdamsNDBurgessJLChaudhariAMDarcyMGDonatelliCALuengoJINewlanderKAParrishCARidgersLHSarpongMASchmidtSJVan AllerGSCarsonJDDiamondMAElkinsPAGardinerCMGarverEGilbertSAGontarekRRJacksonJRKershnerKLLuoLRahaKSherkCSSungCMSuttonDTumminoPJWegrzynRJAugerKRDhanakDDiscovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycinACS Med. </plain></SENT>
<SENT sid="428" pm="."><plain>Chem. </plain></SENT>
<SENT sid="429" pm="."><plain>Lett201013943 </plain></SENT>
</text></ref><ref id="R37"><text><SENT sid="430" pm="."><plain>37KongDYamoriTZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoformsCancer Sci2007981638164217711503 </plain></SENT>
</text></ref><ref id="R38"><text><SENT sid="431" pm="."><plain>38HermanSEGordonALWagnerAJHeeremaNAZhaoWFlynnJMJonesJAndritsosLPuriKDLannuttiBJGieseNAZhangXWeiLByrdJCJohnsonAJPhosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signalsBlood20101162078208820522708 </plain></SENT>
</text></ref><ref id="R39"><text><SENT sid="432" pm="."><plain>39GarlichJRDePDeyNSuJPengXMillerAMuraliRLuYMillsGBKundraVShuHKPengQand DurdenDLExperimental therapeutics, molecular targets, and chemical biology: a vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumour and antiangiogenic activityCancer Res20086820621518172313 </plain></SENT>
</text></ref><ref id="R40"><text><SENT sid="433" pm="."><plain>40MairaSMStaufferFBrueggenJFuretPSchnellCFritschCBrachmannSChenePDe PoverASchoemakerKFabbroDGabrielDSimonenMMurphyLFinanPSellersWGarcia-EcheverriaCIdentification and characterization of NVP-BEZ235, a new orally available dual PI3K/mTor inhibitor with potent in vivo antitumour activityMol. </plain></SENT>
<SENT sid="434" pm="."><plain>Cancer Ther200871851186318606717 </plain></SENT>
</text></ref><ref id="R41"><text><SENT sid="435" pm="."><plain>41MolckovskyASiuLLFirst-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meetingJ. </plain></SENT>
<SENT sid="436" pm="."><plain>Hematol. </plain></SENT>
<SENT sid="437" pm="."><plain>Oncol200812018959794 </plain></SENT>
</text></ref><ref id="R42"><text><SENT sid="438" pm="."><plain>42RobertsonADJacksonSKencheAYaipCParbaharanHand ThompsonPTherapeutic morpholino-substituted compoundsPCT Int WO 2001/53266, July 262001 </plain></SENT>
</text></ref><ref id="R43"><text><SENT sid="439" pm="."><plain>43ChiosisGRosenNSepp-LorenzinoLLY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related familyBioorg. </plain></SENT>
<SENT sid="440" pm="."><plain>Med. </plain></SENT>
<SENT sid="441" pm="."><plain>Chem. </plain></SENT>
<SENT sid="442" pm="."><plain>Lett20011190991311294389 </plain></SENT>
</text></ref><ref id="R44"><text><SENT sid="443" pm="."><plain>44ZaskAKaplanJToral-BarzaLHollanderIYoungMTischlerMGaydosCCinqueMLucasJand YuKSynthesis and Structure-Activity Relationships of Ring-Opened 17-Hydroxywortmannins: Potent Phosphoinositide 3-Kinase Inhibitors with Improved Properties and Anticancer EfficacyJ. </plain></SENT>
<SENT sid="444" pm="."><plain>Med. </plain></SENT>
<SENT sid="445" pm="."><plain>Chem2008511319132318269228 </plain></SENT>
</text></ref><ref id="R45"><text><SENT sid="446" pm="."><plain>45ZhuTGuJYuKLucasJCaiPTsaoRGongYLiFChaudharyIDesaiPRuppenMFawziMGibbonsJAyral-KaloustianSSkotnickiJMansourTZaskAPegylated wortmannin and 17-hydroxywortmannin conjugates as phosphoinositide 3-kinase inhibitors active in human tumour xenograft modelsJ. </plain></SENT>
<SENT sid="447" pm="."><plain>Med. </plain></SENT>
<SENT sid="448" pm="."><plain>Chem2006491373137816480272 </plain></SENT>
</text></ref><ref id="R46"><text><SENT sid="449" pm="."><plain>46HayakawaMKaizawaHMoritomoHKoizumiTOhishiTYamanoMOkadaMOhtaMTsukamotoSRaynaudFIWorkmanPWaterfieldMParkerPSynthesis and biological evaluation of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110α inhibitorsBioorg. </plain></SENT>
<SENT sid="450" pm="."><plain>Med. </plain></SENT>
<SENT sid="451" pm="."><plain>Chem. </plain></SENT>
<SENT sid="452" pm="."><plain>Lett2007172438244217339109 </plain></SENT>
</text></ref><ref id="R47"><text><SENT sid="453" pm="."><plain>47HayakawaMKawaguchiKIKaizawaHTomonobuKOhishiTYamanoMOkadaMOhtaMTsukamotoSRaynaudFIParkerPWorkmanPWaterfieldMDSynthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110α inhibitorsBioorg. </plain></SENT>
<SENT sid="454" pm="."><plain>Med. </plain></SENT>
<SENT sid="455" pm="."><plain>Chem2007155837584417601739 </plain></SENT>
</text></ref><ref id="R48"><text><SENT sid="456" pm="."><plain>48KendallJDRewcastleGWFrederickRMawsonCDennyWAMarshallESBaguleyBCChaussadeCJacksonSPShepherdPRSynthesis, biological evaluation and molecular modelling of sulfonohydrazides as selective PI3K p110 alpha inhibitorsBioorg. </plain></SENT>
<SENT sid="457" pm="."><plain>Med. </plain></SENT>
<SENT sid="458" pm="."><plain>Chem2007157677768717869522 </plain></SENT>
</text></ref><ref id="R49"><text><SENT sid="459" pm="."><plain>49AlexanderRBalasundaramABatchelorMBrookingsDCrepyKCrabbeTDeltentMFDriessensFGillAHarrisSHutchinsonGKulisaCMerrimanMMistryPPartonTTurnerJWhitcombeIWrightS4-(1,3-Thiazol-2-yl) morpholine derivatives as inhibitors of phosphoinositide 3-kinaseBioorg. </plain></SENT>
<SENT sid="460" pm="."><plain>Med. </plain></SENT>
<SENT sid="461" pm="."><plain>Chem. </plain></SENT>
<SENT sid="462" pm="."><plain>Lett2008184316432018625552 </plain></SENT>
</text></ref><ref id="R50"><text><SENT sid="463" pm="."><plain>50CapraroH-GCarvattiGFuretPImbachPLanJPecchiSSchoepferJ3, 6-Distubstituted-imidazo [1,2-b] pyrazines and 3, 5-disubstituted pyrazolo[1,5-a] pyrimidines as phosphatidylinositol-3-kinase inhibitorsPCT Int. </plain></SENT>
<SENT sid="464" pm="."><plain>WO 2008/138889, November 20 2008 </plain></SENT>
</text></ref><ref id="R51"><text><SENT sid="465" pm="."><plain>51AspelBBlairJAGonzalezBNazifTMFeldmanMEAizensteinBHoffmanRWiliamsRLShokatKMKnightZATargeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinasesNature Chem. </plain></SENT>
<SENT sid="466" pm="."><plain>Biol2008469169918849971 </plain></SENT>
</text></ref><ref id="R52"><text><SENT sid="467" pm="."><plain>52ZaskANowakPWVerheijenJCurranKJKaplanJMalwitzDBursavichMGColeDCAyral-KaloustianSYuKRichardDJLefeverMPyrazolpyrimidine analogues and their use as mTOR kinase and PI3 kinase inhibitorsPCT Int. </plain></SENT>
<SENT sid="468" pm="."><plain>WO 2008/115974, September 25 2008 </plain></SENT>
</text></ref><ref id="R53"><text><SENT sid="469" pm="."><plain>53BookerSD’AngeloND’AmicoDCKimTLiuLMeagherKNormanMHPanterKSchenkelLBSmithATamayoNWhittingtonDAXiNYangKPI3 kinase modulators and methods of usePCT Int. </plain></SENT>
<SENT sid="470" pm="."><plain>WO 2009/017822, February 52009 </plain></SENT>
</text></ref><ref id="R54"><text><SENT sid="471" pm="."><plain>54ChengHBhumralkarDDressKRHoffmanJEJohnsonMCKaniaRSLePTQNambuMDPairishMAPleweMBTranKTPyrido (2, 3-d) pyrimidone compounds and their use as PI3 inhibitorsPCT Int. </plain></SENT>
<SENT sid="472" pm="."><plain>WO 2008/032162, March 202008 </plain></SENT>
</text></ref><ref id="R55"><text><SENT sid="473" pm="."><plain>55WhiteSLKesickiEAThorsettEARuanFFarouzFThienpyrimidines for treatment of inflammatory disorders and cancersPCT Int. </plain></SENT>
<SENT sid="474" pm="."><plain>WO 2008/064018, May 292008 </plain></SENT>
</text></ref><ref id="R56"><text><SENT sid="475" pm="."><plain>56PerryBAlexanderRBennettGBuckleyGCeskaTCrabbeTDaleVGowersLHorsleyHJamesLJenkinsKCrepyKKulisaCLightfootHLockCMackSMorganTNicolasALPittWSabinVWrightSAchieving multi-isoform PI3K inhibition in a series of substituted 3,4-dihydro-2H-benzo[1,4]oxazinesBioorg. </plain></SENT>
<SENT sid="476" pm="."><plain>Med. </plain></SENT>
<SENT sid="477" pm="."><plain>Chem. </plain></SENT>
<SENT sid="478" pm="."><plain>Lett2008184700470418644721 </plain></SENT>
</text></ref><ref id="R57"><text><SENT sid="479" pm="."><plain>57CampsMRuckleTJiHArdissoneVRintelenFShawJFerrandiCChabertCGillieronCFranconBMartinTGretenerDPerrinDLeroyDVittePAHirschEWymannMPCirilloRSchwarzMKRommelCBlockade of PI3K gamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritisNature Med20051193694316127437 </plain></SENT>
</text></ref><ref id="R58"><text><SENT sid="480" pm="."><plain>58QuattropaniARueckleTSchwarzMDorbaisJSauerWClevaCDesforgesGThiazole derivatives and their use thereofPCT Int. </plain></SENT>
<SENT sid="481" pm="."><plain>WO 2005/068444, July 282005 </plain></SENT>
</text></ref><ref id="R59"><text><SENT sid="482" pm="."><plain>59BruceIFinanPLeblancCMcCarthyCWhiteheadLBlairNEBloomfieldFCHaylerJKirmanLOzaMSShuklaL5-Phenylthiazole derivatives and use as PI3 kinase inhibitorsPCT Int. </plain></SENT>
<SENT sid="483" pm="."><plain>WO 2003/072557, September 42003 </plain></SENT>
</text></ref><ref id="R60"><text><SENT sid="484" pm="."><plain>60BarvianNCKolzCNParaKSPattWCVisnickMBenzoxazin-3-ones and derivatives thereof as inhibitors of PI3KPCT Int. </plain></SENT>
<SENT sid="485" pm="."><plain>Appl. </plain></SENT>
<SENT sid="486" pm="."><plain>WO 2004/052373 June 242004 </plain></SENT>
</text></ref><ref id="R61"><text><SENT sid="487" pm="."><plain>61ConnollyMKGogliottiRDLeeHTPlummerMSSextonKEVisnickMCycloalkyl and heterocycloalkyl substituted benzothiophenes as therapeutic agentsPCT Int. </plain></SENT>
<SENT sid="488" pm="."><plain>WO 2004/108713, December 16 2004 </plain></SENT>
</text></ref><ref id="R62"><text><SENT sid="489" pm="."><plain>62YuanHPupoMTBloisJSmithAWeisslederRClardyJJosephsonLA stabilized demethoxyviridin derivative inhibits PI3 kinaseBioorg. </plain></SENT>
<SENT sid="490" pm="."><plain>Med. </plain></SENT>
<SENT sid="491" pm="."><plain>Chem. </plain></SENT>
<SENT sid="492" pm="."><plain>Lett2009194223422719523825 </plain></SENT>
</text></ref><ref id="R63"><text><SENT sid="493" pm="."><plain>63FrederickRMawsonCKendallJDChaussadeCRewcastleGWShepherdPRDennyWAPhosphoinositide-3-kinase (PI3K) inhibitors: identification of new scaffolds using virtual screeningBioorg. </plain></SENT>
<SENT sid="494" pm="."><plain>Med. </plain></SENT>
<SENT sid="495" pm="."><plain>Chem. </plain></SENT>
<SENT sid="496" pm="."><plain>Lett2009195842584719748269 </plain></SENT>
</text></ref><ref id="R64"><text><SENT sid="497" pm="."><plain>64GilbertAMNowakPBrooijmansNBursavichMGDehnhardtCDelos SantosEFeldbergLRHollanderIKimSLombardiSParkKVenkatesanAMMallonRNovel purine and pyrazolo[3,4-d]pyrimidine inhibitors of PI3 kinase-alpha: hit to lead studiesBioorg. </plain></SENT>
<SENT sid="498" pm="."><plain>Med. </plain></SENT>
<SENT sid="499" pm="."><plain>Chem. </plain></SENT>
<SENT sid="500" pm="."><plain>Lett201020 63663919969455 </plain></SENT>
</text></ref><ref id="R65"><text><SENT sid="501" pm="."><plain>65VenkatesanAMDehnhardtCMChenZCDelos SantosEDos SantosOBursavichMGilbertAMEllingboeJWAyral-KaloustianSKhafizovaGBrooijmansNMallonRHollanderIFeldbergLLucasJYuKGibbonsJAbrahamRMansourTSNovel imidazolopyrimidines as dual PI3-Kinase/mTOR inhibitorsBioorg. </plain></SENT>
<SENT sid="502" pm="."><plain>Med. </plain></SENT>
<SENT sid="503" pm="."><plain>Chem. </plain></SENT>
<SENT sid="504" pm="."><plain>Lett20102065365619954970 </plain></SENT>
</text></ref><ref id="R66"><text><SENT sid="505" pm="."><plain>66VenkatesanAMDehnhardtCMSantosEDChenZDos SantosOAyral-KaloustianSKhafizovaGBrooijmansNMallonRHollanderIFeldbergLLucasJYuKGibbonsJAbrahamRTChaudharyIMansourTSBis(morpholino-1,3,5-triazine) Derivatives: Potent Adenosine 50-Triphosphate Competitive Phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitorJ. </plain></SENT>
<SENT sid="506" pm="."><plain>Med. </plain></SENT>
<SENT sid="507" pm="."><plain>Chem2010532636264520166697 </plain></SENT>
</text></ref><ref id="R67"><text><SENT sid="508" pm="."><plain>67VenkatesanAMChenZDos SantosODehnhardtCDelos SantosEAyral-KaloustianSMallonRHollanderIFeldbergLLucasJYuKChaudharyIMansourTSPKI-179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitorBioorg. </plain></SENT>
<SENT sid="509" pm="."><plain>Med. </plain></SENT>
<SENT sid="510" pm="."><plain>Chem. </plain></SENT>
<SENT sid="511" pm="."><plain>Lett2010205869587320797855 </plain></SENT>
</text></ref><ref id="R68"><text><SENT sid="512" pm="."><plain>68ChenZVenkatesanAMDos SantosOSantosEDDehnhardtCMAyral-KaloustianSAshcroftJMcDonaldLAMansourTSStereoselective Synthesis of an active metabolite of the potent PI3 kinase inhibitor PKI-179J. </plain></SENT>
<SENT sid="513" pm="."><plain>Org. </plain></SENT>
<SENT sid="514" pm="."><plain>Chem2010751643165120112997 </plain></SENT>
</text></ref><ref id="R69"><text><SENT sid="515" pm="."><plain>69DehnhardtCMVenkatesanAMSantosE DChenZSantosOKaloustianSABrooijmansNMallonRHollanderIFeldbergLLucasJChaudharyIYuKGibbonsJAbrahamRMansourTSLead optimization of N-3-substituted 7-moroholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: Discovery of PKI-402J. </plain></SENT>
<SENT sid="516" pm="."><plain>Med Chem20105379881019968288 </plain></SENT>
</text></ref><ref id="R70"><text><SENT sid="517" pm="."><plain>70ZhangNAyral-KaloustianSAndersonJTNguyenTDasSVenkatesanAMBrooijmansNLucasJYuKHollanderIMallonR5-Ureidobenzofuranone indoles as potent and efficacious inhibitors of PI3-kinase a and mTOR for the treatment of breast cancerBioorg. </plain></SENT>
<SENT sid="518" pm="."><plain>Med. </plain></SENT>
<SENT sid="519" pm="."><plain>Chem. </plain></SENT>
<SENT sid="520" pm="."><plain>Lett2010203526352920483602 </plain></SENT>
</text></ref><ref id="R71"><text><SENT sid="521" pm="."><plain>71VenkatesanAMChenZDos SantosOBrooijmansNGopalsamyA7H-pyrrolo[2,3-H]quinazoline compounds, their use as mTOR kinase and PI3 kinase inhibitors, and their synthesisPCT Int. </plain></SENT>
<SENT sid="522" pm="."><plain>WO 2009/111547. </plain></SENT>
<SENT sid="523" pm="."><plain>September 112009 </plain></SENT>
</text></ref><ref id="R72"><text><SENT sid="524" pm="."><plain>72ChenZVenkatesanAMDehnhardtCMAyral-KaloustianSBrooijmansNMallonRFeldbergLHollanderILucasJYuKKongFMansourTSSynthesis and SAR of Novel 4-Morpholinopyrrolopyrimidine Derivatives as Potent Phosphatidylinositol 3-Kinase InhibitorsJ. </plain></SENT>
<SENT sid="525" pm="."><plain>Med. </plain></SENT>
<SENT sid="526" pm="."><plain>Chem2010533169318220334367 </plain></SENT>
</text></ref><ref id="R73"><text><SENT sid="527" pm="."><plain>73ChenZVenkatesanAMZaskAVerheijenJCAyral-KaloustianSMansourTSCurranKJ(2-Aryl-7H-pyrrolo[2,3-d]pyridimidin-4-yl)morpholine compounds, their use as mTOR kinase and PI3 kinase inhibitors, and their sythesesPCT Int. </plain></SENT>
<SENT sid="528" pm="."><plain>WO 2010/002954, January 72010 </plain></SENT>
</text></ref><ref id="R74"><text><SENT sid="529" pm="."><plain>74MontagneCBombrumADesforgesGQuattropaniAGaillardP2-Morpholino-pyrido[3,2-d]pyrimidinesPCT Int. </plain></SENT>
<SENT sid="530" pm="."><plain>Pat. </plain></SENT>
<SENT sid="531" pm="."><plain>WO 2010/091996, August 192010 </plain></SENT>
</text></ref><ref id="R75"><text><SENT sid="532" pm="."><plain>75CardinDPGaulinJLGreenspanPDVyskocilSXuTRenouCCThiophene or thiazole derivatives and their use a PI3K inhibitorsPCT Int. </plain></SENT>
<SENT sid="533" pm="."><plain>Pat. </plain></SENT>
<SENT sid="534" pm="."><plain>WO 2009/154741, December 232009 </plain></SENT>
</text></ref><ref id="R76"><text><SENT sid="535" pm="."><plain>76RenouCCThiophenes and their use as phosphatidylinositol 3-kinase (PI3K) inhibitorsPCT Int. </plain></SENT>
<SENT sid="536" pm="."><plain>Pat. </plain></SENT>
<SENT sid="537" pm="."><plain>WO 2009/094224, July 302009 </plain></SENT>
</text></ref><ref id="R77"><text><SENT sid="538" pm="."><plain>77BoYYBookerSBryanMDeakHLLiuLAndrewsKNishimuraNNormaMHPanterKSchenkelLSiegmundACTamayoNAYangKInhibitors of PI3 KinasePCT Int. </plain></SENT>
<SENT sid="539" pm="."><plain>Pat. </plain></SENT>
<SENT sid="540" pm="."><plain>WO 2009/155121, December 232009 </plain></SENT>
</text></ref><ref id="R78"><text><SENT sid="541" pm="."><plain>78BoezioAChengACCoatsJRCopelandKWGraceffaRHarmangeJ-CHuangHLaDOlivieriPRPetersonEASchenkelLIndole/benzimidazole compounds as mTOR kinase inhibitorsPCT Int. </plain></SENT>
<SENT sid="542" pm="."><plain>Pat. </plain></SENT>
<SENT sid="543" pm="."><plain>WO 2010/096314, August 262010 </plain></SENT>
</text></ref><ref id="R79"><text><SENT sid="544" pm="."><plain>79BoYYLiuLNishimuraNNormanMHSiegmundACTamayoNAYangKInhibitors of PI3 kinasePCT Int. </plain></SENT>
<SENT sid="545" pm="."><plain>Pat. </plain></SENT>
<SENT sid="546" pm="."><plain>Appl. </plain></SENT>
<SENT sid="547" pm="."><plain>WO 2010/120094, October 12010 </plain></SENT>
</text></ref><ref id="R80"><text><SENT sid="548" pm="."><plain>80RewcastleGWShepherdPRChaussadeCDennyWAGamageSASubstituted pyrimidines and triazines and their use in cancer therapyPCT Int. </plain></SENT>
<SENT sid="549" pm="."><plain>Pat. </plain></SENT>
<SENT sid="550" pm="."><plain>WO 2009/120094, October 12009 </plain></SENT>
</text></ref><ref id="R81"><text><SENT sid="551" pm="."><plain>81HeffronTPBerryMCastanedoGChangCChuckowreeIDotsonJFolkesAGunznerJLesnickJDLewisCMathieuSNonomiyaJOliveroAPangJPetersonDSalphatiLSampathDSiderisSSutherlinDPTsuiVWanNCWangSWongSZhuB-YIdentification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitorBioorg. </plain></SENT>
<SENT sid="552" pm="."><plain>Med. </plain></SENT>
<SENT sid="553" pm="."><plain>Chem. </plain></SENT>
<SENT sid="554" pm="."><plain>Lett2010202408241120346656 </plain></SENT>
</text></ref><ref id="R82"><text><SENT sid="555" pm="."><plain>82CaiXZhaiHLaiC-JQianCPhosphoinositide-3-kinase inhibitors with a zinc binding moietyPCT Int. </plain></SENT>
<SENT sid="556" pm="."><plain>Pat. </plain></SENT>
<SENT sid="557" pm="."><plain>WO 2010/080996, July 152010 </plain></SENT>
</text></ref><ref id="R83"><text><SENT sid="558" pm="."><plain>83BaikT-GMaSBuhrCANussJMPyridopyrimidinone inhibitors of PI3K? and mTORPCT Int. </plain></SENT>
<SENT sid="559" pm="."><plain>Pat. </plain></SENT>
<SENT sid="560" pm="."><plain>WO 2010/039740, April 82010 </plain></SENT>
</text></ref><ref id="R84"><text><SENT sid="561" pm="."><plain>84ChengHBagrodiaSBaileySEdwardsMHoffmanJHuQKaniaRKnightonDRMarxMANinkovicSSunSZhangEDiscovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug designMed. </plain></SENT>
<SENT sid="562" pm="."><plain>Chem. </plain></SENT>
<SENT sid="563" pm="."><plain>Commun20101139144 </plain></SENT>
</text></ref><ref id="R85"><text><SENT sid="564" pm="."><plain>85FairhurstRAImbachPOrganic compoundsPCT Int. </plain></SENT>
<SENT sid="565" pm="."><plain>Pat. </plain></SENT>
<SENT sid="566" pm="."><plain>WO 2009/080705, July 22009 </plain></SENT>
</text></ref><ref id="R86"><text><SENT sid="567" pm="."><plain>86CaravettiGFairhurstRAFuretPGuagnanoVImbachPOrganic compoundsPCT Int. </plain></SENT>
<SENT sid="568" pm="."><plain>Pat. </plain></SENT>
<SENT sid="569" pm="."><plain>WO 2010/029082, March 182010 </plain></SENT>
</text></ref><ref id="R87"><text><SENT sid="570" pm="."><plain>87KimDJunHLeeHHongSSHongSDevelopment of New Fluorescent Xanthines as Kinase InhibitorsOrg. </plain></SENT>
<SENT sid="571" pm="."><plain>Lett2010121212121520184370 </plain></SENT>
</text></ref><ref id="R88"><text><SENT sid="572" pm="."><plain>88ChengHJohnsonTWHoffmanJEGuoLCLiuZJohnsonTOLiuKKCImidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositionsPCT Int. </plain></SENT>
<SENT sid="573" pm="."><plain>Pat. </plain></SENT>
<SENT sid="574" pm="."><plain>WO 2010/038165, April 82010 </plain></SENT>
</text></ref><ref id="R89"><text><SENT sid="575" pm="."><plain>89LeeCHANagarajHKMWilliamADWilliamsMXiangZTriazine compounds as kinase inhibitorsPCT Int. </plain></SENT>
<SENT sid="576" pm="."><plain>Pat. </plain></SENT>
<SENT sid="577" pm="."><plain>Appl. </plain></SENT>
<SENT sid="578" pm="."><plain>WO 2009/093981 July 302009 </plain></SENT>
</text></ref><ref id="R90"><text><SENT sid="579" pm="."><plain>90NagarajHKMWilliamsMSohCKPyrazine substituted purinesPCT Int. </plain></SENT>
<SENT sid="580" pm="."><plain>Pat. </plain></SENT>
<SENT sid="581" pm="."><plain>WO 2009/157880, December 302009 </plain></SENT>
</text></ref><ref id="R91"><text><SENT sid="582" pm="."><plain>91MoralesGAWeberKTNewblomJMPengXSuJGarlichJRThienopyranones as kinase inhibitorsPCT Int. </plain></SENT>
<SENT sid="583" pm="."><plain>Pat. </plain></SENT>
<SENT sid="584" pm="."><plain>Appl., WO 2009/094560, July 302009 </plain></SENT>
</text></ref><ref id="R92"><text><SENT sid="585" pm="."><plain>92StabenSTHeffronTPSutherlinDPBhatSRCastanedoGMChuckowreeISDotsonJFolkesAJFriedmanLSLeeLLesnickJLewisCMurrayJMNonomiyaJOliveroAGPliseEPangJPriorWWSalphatiLRougeLSampathDTsuiVWanNCWangSWeismannCWuPZhuB-YStructure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinaseBioorg. </plain></SENT>
<SENT sid="586" pm="."><plain>Med. </plain></SENT>
<SENT sid="587" pm="."><plain>Chem. </plain></SENT>
<SENT sid="588" pm="."><plain>Lett2010206048605120822905 </plain></SENT>
</text></ref><ref id="R93"><text><SENT sid="589" pm="."><plain>93LargeJMTorrJERaynaudFIClarkePAHayesAdi StefanoFUrbanFShuttleworthSJSaghirNSheldrakePWorkmanPMcDonaldEPreparation and evaluation of trisubstituted pyrimidines as phosphatidylinositol 3-kinase inhibitors3-Hydroxyphenol analogues and bioisosteric replacements. </plain></SENT>
<SENT sid="590" pm="."><plain>Bioorg. </plain></SENT>
<SENT sid="591" pm="."><plain>Med. </plain></SENT>
<SENT sid="592" pm="."><plain>Chem201119836851 </plain></SENT>
</text></ref><ref id="R94"><text><SENT sid="593" pm="."><plain>94FjellströmOGustafssonDJacksonSLundbergJEnantiomerically pure (-) 2-[1-(7-methyl-2-(morpholin-4-yl)4-oxo-4H-pyrido [1,2-a]pyrimidin-9-yl)ethylamino]benzoic acid, its use in medical therapy, and a pharmaceutical composition comprising itPCT Int. </plain></SENT>
<SENT sid="594" pm="."><plain>Pat. </plain></SENT>
<SENT sid="595" pm="."><plain>Appl., WO 2009/093972, July 302009 </plain></SENT>
</text></ref><ref id="R95"><text><SENT sid="596" pm="."><plain>95HentemanMFScottWWoodJJohnsonJRedmanABullionA-MGuernonLSulfone substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesisPCT Int. </plain></SENT>
<SENT sid="597" pm="."><plain>Pat., 2009, WO 2009/091550, July 232009 </plain></SENT>
</text></ref><ref id="R96"><text><SENT sid="598" pm="."><plain>96RamsdenNBellKCansfieldATaylorJSunoseMMiddlemissD2-Aminoimidazo[1,2-b]pyridazine derivatives as PI3K inhibitorsPCT Int. </plain></SENT>
<SENT sid="599" pm="."><plain>Pat. </plain></SENT>
<SENT sid="600" pm="."><plain>Appl., WO 2010/007099, January 212010 </plain></SENT>
</text></ref><ref id="R97"><text><SENT sid="601" pm="."><plain>97RamsdenNBellKCansfieldATaylorJSunoseMMiddlemissDEllardK7-Substituted amino triazoles as PI3K inhibitorsPCT Int. </plain></SENT>
<SENT sid="602" pm="."><plain>Pat. </plain></SENT>
<SENT sid="603" pm="."><plain>Appl., WO 2010/007100, January 212010 </plain></SENT>
</text></ref><ref id="R98"><text><SENT sid="604" pm="."><plain>98RamsdenNBellKTaylorJSunoseMMiddlemissDEllardKUrea triazololo[1,5-a]pyridine derivatives as PI3K inhibitorsPCT Int. </plain></SENT>
<SENT sid="605" pm="."><plain>Pat. </plain></SENT>
<SENT sid="606" pm="."><plain>Appl., WO 2010/092015, August 192010 </plain></SENT>
</text></ref><ref id="R99"><text><SENT sid="607" pm="."><plain>99RenPLiuYLiLChanKWilsonTEBenzothiazole kinase inhibitors and methods of usePCT Int. </plain></SENT>
<SENT sid="608" pm="."><plain>Pat. </plain></SENT>
<SENT sid="609" pm="."><plain>Appl., WO 2009/114874, September 17 2009 </plain></SENT>
</text></ref><ref id="R100"><text><SENT sid="610" pm="."><plain>100RenPLiuYLiLChanKWilsonTEHeterocyclic Kinase inhibitorsPCT Int. </plain></SENT>
<SENT sid="611" pm="."><plain>Pat. </plain></SENT>
<SENT sid="612" pm="."><plain>Appl., WO 2010/036380 2010 </plain></SENT>
</text></ref><ref id="R101"><text><SENT sid="613" pm="."><plain>101SwinnenDJorand-LebrunCGrippi-VallottonTGerberPGonzalezJShawJPFused bicyclic compounds and the use thereof as PI3K inhibitorsPCT Int. </plain></SENT>
<SENT sid="614" pm="."><plain>Pat. </plain></SENT>
<SENT sid="615" pm="."><plain>Appl., WO 2009/133127, May 112009 </plain></SENT>
</text></ref><ref id="R102"><text><SENT sid="616" pm="."><plain>102SwinnenDJorand-LebrunCGrippi-VallottonTGerberPGonzalezJShawJPJeyaprakashnaryananSFused bicyclic compounds as inhibitors for PI3 kinasePCT Int. </plain></SENT>
<SENT sid="617" pm="."><plain>Pat. </plain></SENT>
<SENT sid="618" pm="."><plain>Appl., WO 2010/100144, September 102010 </plain></SENT>
</text></ref><ref id="R103"><text><SENT sid="619" pm="."><plain>103PomelVGaillardPDesforgesGQuattropaniAMontagneC4-Morpholino-pyrido[3,2-d]pyrimidinesPCT Int. </plain></SENT>
<SENT sid="620" pm="."><plain>Pat. </plain></SENT>
<SENT sid="621" pm="."><plain>Appl., WO 2010/037765, August 42010 </plain></SENT>
</text></ref><ref id="R104"><text><SENT sid="622" pm="."><plain>104WangTAronovSCornebiseMMaltaisFLedeboerMLe TiranAMaroneVMessersmithDCottrelliKInhibitors of phosphatidylinositol 3-kinasePCT Int. </plain></SENT>
<SENT sid="623" pm="."><plain>Pat. </plain></SENT>
<SENT sid="624" pm="."><plain>Appl., WO 2009/12911, October 22 2009 </plain></SENT>
</text></ref><ref id="R105"><text><SENT sid="625" pm="."><plain>105BruceIBuddEEdwardsLHowshamCOrganic compoundsPCT Int. </plain></SENT>
<SENT sid="626" pm="."><plain>Pat. </plain></SENT>
<SENT sid="627" pm="."><plain>Appl., WO 2009/115517, September 242009 </plain></SENT>
</text></ref><ref id="R106"><text><SENT sid="628" pm="."><plain>106KnightZAGonzalezBFeldmanMEZunderE RGoldenbergDDWilliamsOLoewithRStokoeDBallaATothBBallaTWeissWAWilliamsRLShokatK MA pharmacological map of the PI3-K family defines a role for p110αlpha in insulin signallingCell200612573374716647110 </plain></SENT>
</text></ref><ref id="R107"><text><SENT sid="629" pm="."><plain>107KnightZASmall molecule inhibitors of the PI3-kinase familyCurr. </plain></SENT>
<SENT sid="630" pm="."><plain>Top. </plain></SENT>
<SENT sid="631" pm="."><plain>Microbiol. </plain></SENT>
<SENT sid="632" pm="."><plain>Immunol201034726327820473788 </plain></SENT>
</text></ref><ref id="R108"><text><SENT sid="633" pm="."><plain>108YapTASandhuSKWorkmanPde BonoJSEnvisioning the future of early anticancer drug developmentNat. </plain></SENT>
<SENT sid="634" pm="."><plain>Rev. </plain></SENT>
<SENT sid="635" pm="."><plain>Cancer20101051452320535131 </plain></SENT>
</text></ref><ref id="R109"><text><SENT sid="636" pm="."><plain>109CoughlinCMJohnstonDSStrahsABurczynskiMEBacusSHillJFeingoldJMZacharchukCBerkenblitAApproaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapyBreast Cancer Res. </plain></SENT>
<SENT sid="637" pm="."><plain>Treat201012411120803067 </plain></SENT>
</text></ref><ref id="R110"><text><SENT sid="638" pm="."><plain>110AndersenJNSathyanarayananSDi BaccoAChiAZhangTChenA HDolinskiBKrausMRobertsBArthurWKlinghofferRAGarganoDLiLFeldmanILynchBRushJHendricksonR CBlume-JensenPPaweletzC PPathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitorsSci. </plain></SENT>
<SENT sid="639" pm="."><plain>Transl. </plain></SENT>
<SENT sid="640" pm="."><plain>Med201024355 </plain></SENT>
</text></ref><ref id="R111"><text><SENT sid="641" pm="."><plain>111GuillardSClarkePATe PoeleRMohriZBjerkeLValentiMRaynaudFEcclesS AWorkmanPMolecular pharmacology of phosphatidylinositol 3-kinase inhibition in human gliomaCell Cycle2009844345319177002 </plain></SENT>
</text></ref><ref id="R112"><text><SENT sid="642" pm="."><plain>112SarkerDClarkePAWelshLRaynaudFValentiMTandyDTitleyIEcclesSGarrettMWorkmanPUse of gene expression microarrays to identify novel pharmacodynamic biomarkers of phosphatidylinositide-3’-kinase (PI3K) inhibitionProc. </plain></SENT>
<SENT sid="643" pm="."><plain>AACR Meeting Abstracts2008abstr. </plain></SENT>
<SENT sid="644" pm="."><plain>3614 </plain></SENT>
</text></ref><ref id="R113"><text><SENT sid="645" pm="."><plain>113WilliamsRBakerA FIhleNTWinklerARKirkpatrickLPowisGThe skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signallingCancer Chemother. </plain></SENT>
<SENT sid="646" pm="."><plain>Pharmacol20065844445016485116 </plain></SENT>
</text></ref><ref id="R114"><text><SENT sid="647" pm="."><plain>114SerraVMarkmanBScaltritiMEichhornPJValeroVGuzmanMBoteroMLLlonchEAtzoriFDi CosimoSMairaMGarcia-EcheverriaCParraJLArribasJBaselgaJNVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signalling and inhibits the growth of cancer cells with activating PI3K mutationsCancer Res2008688022803018829560 </plain></SENT>
</text></ref><ref id="R115"><text><SENT sid="648" pm="."><plain>115MarkmanBLoRussoPMPatnaikAHeathELairdADvan LeeuwenBA phase I dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL765, a novel inhibitor of PI3K and mTOR, administered orally to patients with solid tumoursEur. </plain></SENT>
<SENT sid="649" pm="."><plain>J. </plain></SENT>
<SENT sid="650" pm="."><plain>Cancer20086216 </plain></SENT>
</text></ref><ref id="R116"><text><SENT sid="651" pm="."><plain>116BaselgaJDe JongeMJRodonJBurris IIIHABirleDCDe BuckSSDemanseDRuQCGoldbrunnerMBendellJCA first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumoursJ. </plain></SENT>
<SENT sid="652" pm="."><plain>Clin. </plain></SENT>
<SENT sid="653" pm="."><plain>Oncol. </plain></SENT>
<SENT sid="654" pm="."><plain>(ASCO Meeting Abstracts)2010283003 </plain></SENT>
</text></ref><ref id="R117"><text><SENT sid="655" pm="."><plain>117BairdRDKristeleitRSSarkerDOlmosDSandhuSKYanYKoeppenHLevyGGJinJDe BonoJSA phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral panphosphoinositide-3 kinase (PI3K) inhibitor GDC-0941J. </plain></SENT>
<SENT sid="656" pm="."><plain>Clin. </plain></SENT>
<SENT sid="657" pm="."><plain>Oncol. </plain></SENT>
<SENT sid="658" pm="."><plain>(ASCO Meeting Abstracts)2010282613 </plain></SENT>
</text></ref><ref id="R118"><text><SENT sid="659" pm="."><plain>118Von HoffDDLoRussoPTibesRShapiroGWeissGJWareJAFredricksonJMazinaKELevyGGWagnerAJA first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumoursJ. </plain></SENT>
<SENT sid="660" pm="."><plain>Clin. </plain></SENT>
<SENT sid="661" pm="."><plain>Oncol. </plain></SENT>
<SENT sid="662" pm="."><plain>(ASCO Meeting Abstracts)2010282541 </plain></SENT>
</text></ref><ref id="R119"><text><SENT sid="663" pm="."><plain>119SoriaJCGomez-RocaCAWareJAAdjeiAABrachmannRKGroenHJMA Phase Ib study to evaluate the pan-PI3K inhibitor GDC-0941 with paclitaxel and carboplatin with and without bevacizumab in non-small cell lung cancer patientsEur. </plain></SENT>
<SENT sid="664" pm="."><plain>J. </plain></SENT>
<SENT sid="665" pm="."><plain>Cancer20108421 </plain></SENT>
</text></ref><ref id="R120"><text><SENT sid="666" pm="."><plain>120DollySWagnerAJBendellJCYanYWareJAMazinaKEHoldenSNDerynckMKDe BonoJSBurris IIIHAA first-in-human, phase I study to evaluate the dual PI3K/mTOR inhibitor GDC-0980 administered QD in patients with advanced solid tumours or non-Hodgkin's lymphomaJ. </plain></SENT>
<SENT sid="667" pm="."><plain>Clin. </plain></SENT>
<SENT sid="668" pm="."><plain>Oncol. </plain></SENT>
<SENT sid="669" pm="."><plain>(ASCO Meeting Abstracts)2010283079 </plain></SENT>
</text></ref><ref id="R121"><text><SENT sid="670" pm="."><plain>121EdelmanGBedellCShapiroGPandyaSSKwakELScheffoldCNguyenLTLairdABaselgaJA phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignanciesJ. </plain></SENT>
<SENT sid="671" pm="."><plain>Clin. </plain></SENT>
<SENT sid="672" pm="."><plain>Oncol. </plain></SENT>
<SENT sid="673" pm="."><plain>(ASCO Meeting Abstracts)2010283004 </plain></SENT>
</text></ref><ref id="R122"><text><SENT sid="674" pm="."><plain>122ShapiroGKwakEBaselgaJRodonJScheffoldCLairdADBedellCEdelmanGPhase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumorsJ. </plain></SENT>
<SENT sid="675" pm="."><plain>Clin. </plain></SENT>
<SENT sid="676" pm="."><plain>Oncol. </plain></SENT>
<SENT sid="677" pm="."><plain>(ASCO Meeting Abstracts)2009273500 </plain></SENT>
</text></ref><ref id="R123"><text><SENT sid="678" pm="."><plain>123HerbstRSFalchookGSMessersmithWACamidgeDRPetersonSRHausmanDFKurzrockREckhardtSGHongDSA Phase I study of continuous dosing with PX-866 an irreversible pan-isoform inhibitor of PI3KEur. </plain></SENT>
<SENT sid="679" pm="."><plain>J. </plain></SENT>
<SENT sid="680" pm="."><plain>Cancer20108366 </plain></SENT>
</text></ref><ref id="R124"><text><SENT sid="681" pm="."><plain>124BranaILoRussoPBaselgaJHeathEIPatnaikAGendreauASLairdAPapadopoulosKA phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced malignanciesJ. </plain></SENT>
<SENT sid="682" pm="."><plain>Clin. </plain></SENT>
<SENT sid="683" pm="."><plain>Oncol. </plain></SENT>
<SENT sid="684" pm="."><plain>(ASCO Meeting Abstracts)2010283030 </plain></SENT>
</text></ref><ref id="R125"><text><SENT sid="685" pm="."><plain>125NghiemphuPLOmuroAMCloughesyTMellinghoffIKNordenADNguyenLTRajangamKWenPYA phase I safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with newly diagnosed malignant gliomaJ. </plain></SENT>
<SENT sid="686" pm="."><plain>Clin. </plain></SENT>
<SENT sid="687" pm="."><plain>Oncol. </plain></SENT>
<SENT sid="688" pm="."><plain>(ASCO Meeting Abstracts)2010283085 </plain></SENT>
</text></ref><ref id="R126"><text><SENT sid="689" pm="."><plain>126CohenRBJannePAEngelmanJAMartínezPNishidaYGendreauSWuBFelipEA phase I safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor XL765 (SAR245409) in combination with erlotinib (E) in patients (pts) with advanced solid tumoursJ. </plain></SENT>
<SENT sid="690" pm="."><plain>Clin. </plain></SENT>
<SENT sid="691" pm="."><plain>Oncol. </plain></SENT>
<SENT sid="692" pm="."><plain>(ASCO Meeting Abstracts)2010283015 </plain></SENT>
</text></ref><ref id="R127"><text><SENT sid="693" pm="."><plain>127FurmanRByrdJCFlinnIWCoutreSEBenson JrDMBrownJRKahlBSWagner-JohnstonNDGieseNAYuASInterim results from a phase I study of CAL-101, a selective oral inhibitor of phosphatidylinositol 3-kinase p110d isoform, in patients with relapsed or refractory hematologic malignanciesJ. </plain></SENT>
<SENT sid="694" pm="."><plain>Clin. </plain></SENT>
<SENT sid="695" pm="."><plain>Oncol. </plain></SENT>
<SENT sid="696" pm="."><plain>(ASCO Meeting Abstracts)2010283032 </plain></SENT>
</text></ref><ref id="R128"><text><SENT sid="697" pm="."><plain>128EllisLMHicklinDJResistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular OncologyClin. </plain></SENT>
<SENT sid="698" pm="."><plain>Cancer Res2009157471747820008847 </plain></SENT>
</text></ref><ref id="R129"><text><SENT sid="699" pm="."><plain>129BoydZSWuQJO'BrienCSpoerkeJSavageHFielderPJAmlerLYanYLacknerMRProteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarraysMol. </plain></SENT>
<SENT sid="700" pm="."><plain>Cancer Ther200873695370619056674 </plain></SENT>
</text></ref><ref id="R130"><text><SENT sid="701" pm="."><plain>130DanSOkamuraMSekiMYamazakiKSugitaHOkuiMMukaiYNishimuraHAsakaRNomuraKIshikawaYYamoriTCorrelating phosphatidylinositol 3-kinase inhibitor efficacy with signalling pathway status: in silico and biological evaluationsCancer Res2010704982499420530683 </plain></SENT>
</text></ref><ref id="R131"><text><SENT sid="702" pm="."><plain>131VasudevanKMBarbieDADaviesMARabinovskyRMcNearCJKimJJHennessyBTTsengHPochanardPKimSYDunnIFSchinzelACSandyPHoerschSShengQGuptaPBBoehmJSReilingJHSilverSLuYStemke-HaleKDuttaBJoyCSahinAAGonzalez-AnguloAMLluchARamehLEJacksTRootDELanderESMillsGBHahnWCSellersWRGarrawayLAAKT-independent signalling downstream of oncogenic PIK3CA mutations in human cancerCancer Cell200916213219573809 </plain></SENT>
</text></ref><ref id="R132"><text><SENT sid="703" pm="."><plain>132Stemke-HaleKGonzalez-AnguloAMLluchANeveRMKuoWLDaviesMCareyMHuZGuanYSahinASymmansWFPusztaiLNoldenLKHorlingsHBernsKHungMCvan de VijverMJValeroVGrayJWBernardsRMillsGBHennessyBTAn integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancerCancer Res2008686084609118676830 </plain></SENT>
</text></ref><ref id="R133"><text><SENT sid="704" pm="."><plain>133BrachmannSMHofmannISchnellCFritschCWeeSLaneHWangSGarcia-EcheverriaCMairaSMSpecific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cellsProc. </plain></SENT>
<SENT sid="705" pm="."><plain>Natl. </plain></SENT>
<SENT sid="706" pm="."><plain>Acad. </plain></SENT>
<SENT sid="707" pm="."><plain>Sci. </plain></SENT>
<SENT sid="708" pm="."><plain>USA2009106222992230420007781 </plain></SENT>
</text></ref><ref id="R134"><text><SENT sid="709" pm="."><plain>134O'BrienCWallinJJSampathDGuhaThakurtaDSavageHPunnooseEAGuanJBerryLPriorWWAmlerLCBelvinMFriedmanLSLacknerMRPredictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical modelsClin. </plain></SENT>
<SENT sid="710" pm="."><plain>Cancer Res2010163670368320453058 </plain></SENT>
</text></ref><ref id="R135"><text><SENT sid="711" pm="."><plain>135IhleNTLemosR JrWipfPYacoubAMitchellCSiwakDMillsGBDentPKirkpatrickDLPowisGMutations in the phosphatidylinositol-3-kinase pathway predict for antitumour activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistanceCancer Res20096914315019117997 </plain></SENT>
</text></ref><ref id="R136"><text><SENT sid="712" pm="."><plain>136EdgarKAWallinJJBerryMLeeLBPriorWWSampathDFriedmanLSBelvinMIsoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumoursCancer Res2010701164117220103642 </plain></SENT>
</text></ref><ref id="R137"><text><SENT sid="713" pm="."><plain>137SosMLFischerSUllrichRPeiferMHeuckmannJMKokerMHeynckSStückrathIWeissJFischerFMichelKGoelARegalesLPolitiKAPereraSGetlikMHeukampLCAnsénSZanderTBeroukhimRKashkarHShokatKMSellersWRRauhDOrrCHoeflichKPFriedmanLWongKKPaoWThomasRKIdentifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancerProc. </plain></SENT>
<SENT sid="714" pm="."><plain>Natl. </plain></SENT>
<SENT sid="715" pm="."><plain>Acad. </plain></SENT>
<SENT sid="716" pm="."><plain>Sci. </plain></SENT>
<SENT sid="717" pm="."><plain>USA2009106183511835619805051 </plain></SENT>
</text></ref><ref id="R138"><text><SENT sid="718" pm="."><plain>138GuptaSRamjaunARHaikoPWangYWarnePHNickeBNyeEStampGAlitaloKDownwardJBinding of ras to phosphoinositide 3-kinase p110αlpha is required for ras-driven tumourigenesis in miceCell200712995796817540175 </plain></SENT>
</text></ref><ref id="R139"><text><SENT sid="719" pm="."><plain>139EngelmanJAChenLTanXCrosbyKGuimaraesARUpadhyayRMairaMMcNamaraKPereraSASongYChirieacLRKaurRLightbownASimendingerJLiTPaderaRFGarcía-EcheverríaCWeisslederRMahmoodUCantleyLCWongKKEffective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersNature Med2008141351135619029981 </plain></SENT>
</text></ref><ref id="R140"><text><SENT sid="720" pm="."><plain>140FaberACLiDSongYLiangMCYeapBYBronsonRTLifshitsEChenZMairaSMGarcía-EcheverríaCWongKKEngelmanJADifferential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibitionProc. </plain></SENT>
<SENT sid="721" pm="."><plain>Natl. </plain></SENT>
<SENT sid="722" pm="."><plain>Acad. </plain></SENT>
<SENT sid="723" pm="."><plain>Sci. </plain></SENT>
<SENT sid="724" pm="."><plain>USA2009106195031950819850869 </plain></SENT>
</text></ref><ref id="R141"><text><SENT sid="725" pm="."><plain>141HammermanPSJannePAJohnsonBEResistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung CancerClin. </plain></SENT>
<SENT sid="726" pm="."><plain>Cancer Res2009157502750920008850 </plain></SENT>
</text></ref><ref id="R142"><text><SENT sid="727" pm="."><plain>142MilojkovicDApperleyJMechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid LeukemiaClin. </plain></SENT>
<SENT sid="728" pm="."><plain>Cancer Res2009157519752720008852 </plain></SENT>
</text></ref><ref id="R143"><text><SENT sid="729" pm="."><plain>143ZunderERKnightZAHousemanBTApselBShokatKMDiscovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alphaCancer Cell20081418019218691552 </plain></SENT>
</text></ref><ref id="R144"><text><SENT sid="730" pm="."><plain>144YapTAGarrettMDWaltonMIRaynaudFde BonoJSWorkmanPTargeting the PI3K-AKT-mTOR pathway: progress, pitfalls and promisesCurr. </plain></SENT>
<SENT sid="731" pm="."><plain>Opin. </plain></SENT>
<SENT sid="732" pm="."><plain>Pharmacol2008839341218721898 </plain></SENT>
</text></ref><ref id="R145"><text><SENT sid="733" pm="."><plain>145SchwertschlagUSChioreanEGAnthonySPSweeneyCJBoradMJvon HoffDDGalrichJRSheltonCFRamanathanRKPhase 1 pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of SF1126 a vascular targeted pan phosphoinositide 3- kinase (PI3K) inhibitor in patients with solid tumoursJ. </plain></SENT>
<SENT sid="734" pm="."><plain>Clin. </plain></SENT>
<SENT sid="735" pm="."><plain>Oncol. </plain></SENT>
<SENT sid="736" pm="."><plain>(ACSO Meeting Abstracts)20082614532 </plain></SENT>
</text></ref><ref id="R146"><text><SENT sid="737" pm="."><plain>146ChioreanEGMahadevanDHarrisWBvon HoffDDYoungerAERensvoldDMSheltonCFHennessyBTGarlichJRRamanathanRKPhase I evaluation of SF1126, a vascular targeted PI3K inhibitor, administered twice weekly IV in patients with refractory solid tumoursJ. </plain></SENT>
<SENT sid="738" pm="."><plain>Clin. </plain></SENT>
<SENT sid="739" pm="."><plain>Oncol. </plain></SENT>
<SENT sid="740" pm="."><plain>(ACSO Meeting Abstracts)2009272558 </plain></SENT>
</text></ref><ref id="R147"><text><SENT sid="741" pm="."><plain>147MoldovanCSoriaJLoRussoPGuthrieTSongCNguyenLTMartiniJInfanteJRBurris IIIHAA phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients (pts) with advanced solid tumoursJ. </plain></SENT>
<SENT sid="742" pm="."><plain>Clin. </plain></SENT>
<SENT sid="743" pm="."><plain>Oncol. </plain></SENT>
<SENT sid="744" pm="."><plain>(ACSO Meeting Abstracts)2010283070 </plain></SENT>
</text></ref><ref id="R148"><text><SENT sid="745" pm="."><plain>148TraynorAMKurzrockRBaleyHHAttiaSScheffoldCvan LeeuwenBWuBFalchookGSMoulderSLWhelerJA phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumorsJ. </plain></SENT>
<SENT sid="746" pm="."><plain>Clin. </plain></SENT>
<SENT sid="747" pm="."><plain>Oncol. </plain></SENT>
<SENT sid="748" pm="."><plain>(ACSO Meeting Abstracts)2010283078 </plain></SENT>
</text></ref><ref id="R149"><text><SENT sid="749" pm="."><plain>149Burris IIIHRodonJSharmaSHerbstRSTaberneroJInfanteJRSilvaADemanseDHacklWBaselgaJFirst-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumoursJ. </plain></SENT>
<SENT sid="750" pm="."><plain>Clin. </plain></SENT>
<SENT sid="751" pm="."><plain>Oncol. </plain></SENT>
<SENT sid="752" pm="."><plain>(ACSO Meeting Abstracts)2010283005 </plain></SENT>
</text></ref><ref id="R150"><text><SENT sid="753" pm="."><plain>150BrittenCDAdjeiAAMillhamRHoukBWainbergZAGuthrieTDyGLoRussoPMFirst-in-human study of PF-04691502, a small molecule oral dual inhibitor of PI3K and mTOR in patients with advanced cancer: Preliminary report on safety and pharmacokineticsEur. </plain></SENT>
<SENT sid="754" pm="."><plain>J. </plain></SENT>
<SENT sid="755" pm="."><plain>Cancer20108383 </plain></SENT>
</text></ref><ref id="R151"><text><SENT sid="756" pm="."><plain>151ShapiroGIMolinaJBendellJBrañaISpicerJKwakEPandyaSMillhamRHoukBBell-McGuinnKFirst-in-human study of PF-05212384, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: preliminary report on safety and pharmacokineticsEur. </plain></SENT>
<SENT sid="757" pm="."><plain>J. </plain></SENT>
<SENT sid="758" pm="."><plain>Cancer20108387 </plain></SENT>
</text></ref><ref id="R152"><text><SENT sid="759" pm="."><plain>152RaynaudFIEcclesSClarkePAHayesANutleyBAlixSHenleyADi-StefanoFAhmadZGuillardSBjerkeLMKellandLValentiMPattersonLGowanSde Haven BrandonAHayakawaMKaizawaHKoizumiTOhishiTPatelSSaghirNParkerPWaterfieldMWorkmanPPharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinasesCancer Res2007675840585017575152 </plain></SENT>
</text></ref><ref id="R153"><text><SENT sid="760" pm="."><plain>153WorkmanPCollinsIProbing the probes: fitness factors for small molecule toolsChem. </plain></SENT>
<SENT sid="761" pm="."><plain>Biol20101756157720609406 </plain></SENT>
</text></ref><ref id="R154"><text><SENT sid="762" pm="."><plain>154van MontfortRLWorkmanPStructure-based design of molecular cancer therapeuticsTrends Biotechnol20092731532819339067 </plain></SENT>
</text></ref><ref id="R155"><text><SENT sid="763" pm="."><plain>155WorkmanPvan MontfortRLUnveiling the secrets of the ancestral PI3 kinase Vps34Cancer Cell20101742142320478524 </plain></SENT>
</text></ref><ref id="R156"><text><SENT sid="764" pm="."><plain>156WorkmanPvan MontfortLPI(3) kinases: revealing the delta ladyNat. </plain></SENT>
<SENT sid="765" pm="."><plain>Chem. </plain></SENT>
<SENT sid="766" pm="."><plain>Biol20106828320081818 </plain></SENT>
</text></ref><ref id="R157"><text><SENT sid="767" pm="."><plain>157JiangXChenSAsaraJMBalkSPPI3K-Pathway Activation in PTEN Deficient Prostate Cancer Cells is Mediated by the p110ß and p110d Catalytic SubunitsJ. </plain></SENT>
<SENT sid="768" pm="."><plain>Biol. </plain></SENT>
<SENT sid="769" pm="."><plain>Chem2010285149801498920231295 </plain></SENT>
</text></ref><ref id="R158"><text><SENT sid="770" pm="."><plain>158DboukHAPangHFiserABackerJMA biochemical mechanism for the oncogenic potential of the p110ß catalytic subunit of phosphoinositide-3 kinaseProc. </plain></SENT>
<SENT sid="771" pm="."><plain>Natl. </plain></SENT>
<SENT sid="772" pm="."><plain>Acad. </plain></SENT>
<SENT sid="773" pm="."><plain>Sci. </plain></SENT>
<SENT sid="774" pm="."><plain>USA2010107198971990221030680 </plain></SENT>
</text></ref><ref id="R159"><text><SENT sid="775" pm="."><plain>159DboukHABackerJMA beta version of life: p110ß takes center stageOncotarget2010172973321321382 </plain></SENT>
</text></ref><ref id="R160"><text><SENT sid="776" pm="."><plain>160ShuttleworthSJCecilARLHillTJSilvaFATricyclic Heterocyclic Compounds as Phosphoinositide 3-Kinase InhibitorsPCT Int. </plain></SENT>
<SENT sid="777" pm="."><plain>Pat., 2011, WO 2011/021038, February 242011 </plain></SENT>
</text></ref><ref id="R161"><text><SENT sid="778" pm="."><plain>161EdlingC ESelvaggiFBuusRMaffucciTDi SebastianoPFriessHInnocentiPKocherH MFalascaMKey role of phosphoinositide 3-kinase class IB in pancreatic cancerClin. </plain></SENT>
<SENT sid="779" pm="."><plain>Cancer Res2010154928493720876794 </plain></SENT>
</text></ref></ref-list></SecTag></back><floats-group><SecTag type="FIG"><fig id="F1" position="float"><label>Fig. (1)</label><caption><p><text><SENT sid="780" pm="."><plain>X-ray co-crystal structure of the pan-class I selective PI3K inhibitor GDC-0941 (3) (PDB Code 3dbs). </plain></SENT>
<SENT sid="781" pm="."><plain>For more details see text and references [3, 33, 34]. </plain></SENT>
</text></p></caption><graphic xlink:href="CMC-18-2686_F1"/></fig></SecTag><SecTag type="TABLE"><table-wrap id="T1" position="float"><label>Table 1</label><table frame="border" rules="all" width="100%"><thead><tr><th rowspan="1" colspan="1"><text><SENT sid="782" pm="."><plain>ENTRY </plain></SENT>
</text></th><th rowspan="1" colspan="1"><text><SENT sid="783" pm="."><plain>STRUCTURE </plain></SENT>
</text></th><th rowspan="1" colspan="1"><text><SENT sid="784" pm="."><plain>COMMENTS </plain></SENT>
</text></th><th rowspan="1" colspan="1"><text><SENT sid="785" pm="."><plain>REF </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="786" pm="."><plain>1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="787" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="788" pm="."><plain>LY294002: IC50 of 0.55µM, 11µM, 1.6µM and 12µM against p110α, β, δ and γ respectively </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="789" pm="."><plain>[28] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="790" pm="."><plain>2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="791" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="792" pm="."><plain>Wortmannin: IC50 of 4, 1nM, 4 and 9nM against p110α, β, δ and γ respectively </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="793" pm="."><plain>[29] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="794" pm="."><plain>3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="795" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="796" pm="."><plain>GDC-0941: IC50 of 3, 33, 3 and 75nM against p110α, β, δ and γ respectively </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="797" pm="."><plain>[33, 34] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="798" pm="."><plain>4 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="799" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="800" pm="."><plain>XL147: IC50 p110α, β, d, γ = 39, 383, 36, and 23nM respectively </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="801" pm="."><plain>[35] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="802" pm="."><plain>5 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="803" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="804" pm="."><plain>GSK1059615: IC50 p110α, β, d, g and mTOR = 0.4, 0.6, 2, 5 and 12nM respectively </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="805" pm="."><plain>[36] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="806" pm="."><plain>6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="807" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="808" pm="."><plain>ZSTK474: IC50 p110α, β, d, γ = 16, 44, 5, and 49nM respectively </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="809" pm="."><plain>[37] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="810" pm="."><plain>7 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="811" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="812" pm="."><plain>PX-866: IC50 p110α, d and γ = 6nM, 3nM and 9nM respectively; p110β &gt; 300μM </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="813" pm="."><plain>[29] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="814" pm="."><plain>8 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="815" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="816" pm="."><plain>CAL-101: IC50 p110α, β, δ and γ = &gt;100μM, 1.82μM, 70nM and 1.24μM respectively </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="817" pm="."><plain>[38] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="818" pm="."><plain>9 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="819" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="820" pm="."><plain>SF1126: IC50 p110α, β, δ and γ = 356, 736, 3225, 1774nM respectively; IC50 mTOR, DNA-PK = 1060 and 357nM respectively </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="821" pm="."><plain>[39] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="822" pm="."><plain>10 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="823" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="824" pm="."><plain>NVP-BEZ235: IC50 p110α, β, d, g and mTOR = 4, 75, 7, 5, 21nM respectively </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="825" pm="."><plain>[40] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="826" pm="."><plain>11 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="827" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="828" pm="."><plain>XL765: IC50 p110α, β, d, g and mTOR= 39, 113, 43, 9 and 157nM respectively </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="829" pm="."><plain>[41] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="830" pm="."><plain>12 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="831" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="832" pm="."><plain>GSK2126458: Ki p110α, β, d, g and mTORC1 = 19, 130, 24, 60 and 180pM respectively </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="833" pm="."><plain>[36] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="834" pm="."><plain>13 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="835" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="836" pm="."><plain>TG100115: IC50 p110α, β, δ and γ = 1.3μM, 1.2μM, 235nM and 83nM respectively </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="837" pm="."><plain>[29] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="838" pm="."><plain>14 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="839" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="840" pm="."><plain>TGX 221: IC50 p110β = 5nM; p110α = 5μM, p110δ = 100nM, p110γ &gt; 10μM </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="841" pm="."><plain>[42] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="842" pm="."><plain>15 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="843" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="844" pm="."><plain>Heterodimer of LY294002 and geldanamycin exhibits activity against PI3K and Hsp90 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="845" pm="."><plain>[43] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="846" pm="."><plain>16 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="847" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="848" pm="."><plain>17-Hydroxywortmannin: IC50 p110α = 2.7nM </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="849" pm="."><plain>[44] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="850" pm="."><plain>17 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="851" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="852" pm="."><plain>PWT-458, a pegylated derivative of 17-hydroxywortmannin with improved tolerability profile compared with 16 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="853" pm="."><plain>[45] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="854" pm="."><plain>18 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="855" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="856" pm="."><plain>PI-103: IC50, p110α = 3.6nM, p110β = 3nM, mTORC1 = 20nM, mTORC2 = 80nM   </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="857" pm="."><plain>[46, 4] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="858" pm="."><plain>19 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="859" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="860" pm="."><plain>IC50, p110α = 7nM, p110γ = 670nM </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="861" pm="."><plain>[34] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="862" pm="."><plain>20 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="863" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="864" pm="."><plain>IC50, p110α = 3nM, p110β = 170nM, p110γ = 230nM   </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="865" pm="."><plain>[47] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="866" pm="."><plain>21 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="867" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="868" pm="."><plain>IC50, p110α = 800nM, p110β &gt;10μM   </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="869" pm="."><plain>[48] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="870" pm="."><plain>22 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="871" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="872" pm="."><plain>IC50 = 59nM, 1.006 µM, 18nM, 31nM for p110 α, p110β, p110δ and p110γ respectively </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="873" pm="."><plain>[49] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="874" pm="."><plain>23 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="875" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="876" pm="."><plain>IC50 p110α = 15nM, p110β =4nM, p110δ = 9nM, p110γ = 737nM </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="877" pm="."><plain>[50] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="878" pm="."><plain>24 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="879" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="880" pm="."><plain>IC50, p110α, DNA-PK and mTOR of 52nM, 60nM and 10nM respectively; IC50  p110β and p110γ = 1.4µM and 1.1µM respectively </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="881" pm="."><plain>[51] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="882" pm="."><plain>25 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="883" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="884" pm="."><plain>IC50, p110α = 11nM, mTOR = 17.5nM; GI50, LNCaP = 450nM, MDA468 = 1.7µM </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="885" pm="."><plain>[52] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="886" pm="."><plain>26 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="887" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="888" pm="."><plain>IC50, p110α = 29nM, p110β = 5.2µM </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="889" pm="."><plain>[53] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="890" pm="."><plain>27 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="891" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="892" pm="."><plain>IC50, p110α = 3nM, p110β = 3.8nM </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="893" pm="."><plain>[53] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="894" pm="."><plain>28 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="895" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="896" pm="."><plain>IC50, p110α = 500pM </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="897" pm="."><plain>[54] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="898" pm="."><plain>29 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="899" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="900" pm="."><plain>IC50, p110δ = 3nM; &gt;60-fold selectivity over p110γ; &gt;200-fold specificity over p110α, p110β, DNA-PK and mTOR. </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="901" pm="."><plain>[51] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="902" pm="."><plain>30 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="903" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="904" pm="."><plain>Ki, p110δ = 5nM </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="905" pm="."><plain>[55] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="906" pm="."><plain>31 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="907" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="908" pm="."><plain>IC50, p110δ = 14nM; IC50, p110γ = 52nM </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="909" pm="."><plain>[56] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="910" pm="."><plain>32 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="911" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="912" pm="."><plain>AS-605340: IC50, p110γ = 8nM </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="913" pm="."><plain>[57] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="914" pm="."><plain>33 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="915" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="916" pm="."><plain>IC50, p110γ = 10nM  IC50, p-AKT = 3.18µM </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="917" pm="."><plain>[58] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="918" pm="."><plain>34 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="919" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="920" pm="."><plain>IC50, p110γ = 2nM </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="921" pm="."><plain>[59] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="922" pm="."><plain>35 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="923" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="924" pm="."><plain>IC50, p110γ = 3nM </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="925" pm="."><plain>[60] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="926" pm="."><plain>36 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="927" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="928" pm="."><plain>IC50, p110γ = 3nM </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="929" pm="."><plain>[61] </plain></SENT>
</text></td></tr></tbody></table></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="T2" position="float"><label>Table 2</label><table frame="border" rules="all" width="100%"><thead><tr><th rowspan="1" colspan="1"><text><SENT sid="930" pm="."><plain>ENTRY </plain></SENT>
</text></th><th rowspan="1" colspan="1"><text><SENT sid="931" pm="."><plain>STRUCTURE </plain></SENT>
</text></th><th rowspan="1" colspan="1"><text><SENT sid="932" pm="."><plain>REF </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="933" pm="."><plain>37 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="934" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="935" pm="."><plain>[62] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="936" pm="."><plain>38 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="937" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="938" pm="."><plain>[63] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="939" pm="."><plain>39 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="940" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="941" pm="."><plain>[64] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="942" pm="."><plain>40 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="943" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="944" pm="."><plain>[64] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="945" pm="."><plain>41 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="946" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="947" pm="."><plain>[65] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="948" pm="."><plain>42 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="949" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="950" pm="."><plain>[66] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="951" pm="."><plain>43 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="952" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="953" pm="."><plain>[67] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="954" pm="."><plain>44 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="955" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="956" pm="."><plain>[68] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="957" pm="."><plain>45 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="958" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="959" pm="."><plain>[69] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="960" pm="."><plain>46 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="961" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="962" pm="."><plain>[70] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="963" pm="."><plain>47 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="964" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="965" pm="."><plain>[71] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="966" pm="."><plain>48 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="967" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="968" pm="."><plain>[71] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="969" pm="."><plain>49 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="970" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="971" pm="."><plain>[72] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="972" pm="."><plain>50 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="973" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="974" pm="."><plain>[72] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="975" pm="."><plain>51 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="976" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="977" pm="."><plain>[73] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="978" pm="."><plain>52 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="979" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="980" pm="."><plain>[73] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="981" pm="."><plain>53 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="982" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="983" pm="."><plain>[74] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="984" pm="."><plain>54 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="985" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="986" pm="."><plain>[75] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="987" pm="."><plain>55 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="988" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="989" pm="."><plain>[76] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="990" pm="."><plain>56 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="991" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="992" pm="."><plain>[77] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="993" pm="."><plain>57 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="994" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="995" pm="."><plain>[78] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="996" pm="."><plain>58 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="997" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="998" pm="."><plain>[79] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="999" pm="."><plain>59 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1000" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1001" pm="."><plain>[80] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="1002" pm="."><plain>60 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1003" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1004" pm="."><plain>[81] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="1005" pm="."><plain>61 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1006" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1007" pm="."><plain>[82] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="1008" pm="."><plain>62 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1009" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1010" pm="."><plain>[83] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="1011" pm="."><plain>63 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1012" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1013" pm="."><plain>[84] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="1014" pm="."><plain>64 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1015" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1016" pm="."><plain>[85] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="1017" pm="."><plain>65 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1018" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1019" pm="."><plain>[85] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="1020" pm="."><plain>66 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1021" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1022" pm="."><plain>[86] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="1023" pm="."><plain>67 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1024" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1025" pm="."><plain>[86] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="1026" pm="."><plain>68 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1027" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1028" pm="."><plain>[87] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="1029" pm="."><plain>69 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1030" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1031" pm="."><plain>[88] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="1032" pm="."><plain>70 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1033" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1034" pm="."><plain>[89] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="1035" pm="."><plain>71 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1036" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1037" pm="."><plain>[90] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="1038" pm="."><plain>72 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1039" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1040" pm="."><plain>[91] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="1041" pm="."><plain>73 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1042" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1043" pm="."><plain>[92] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="1044" pm="."><plain>74 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1045" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1046" pm="."><plain>[92] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="1047" pm="."><plain>75 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1048" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1049" pm="."><plain>[93] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="1050" pm="."><plain>76 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1051" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1052" pm="."><plain>[94] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="1053" pm="."><plain>77 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1054" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1055" pm="."><plain>[95] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="1056" pm="."><plain>78 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1057" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1058" pm="."><plain>[96] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="1059" pm="."><plain>79 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1060" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1061" pm="."><plain>[97] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="1062" pm="."><plain>80 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1063" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1064" pm="."><plain>[98] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="1065" pm="."><plain>81 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1066" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1067" pm="."><plain>[99] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="1068" pm="."><plain>82 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1069" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1070" pm="."><plain>[100] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="1071" pm="."><plain>83 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1072" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1073" pm="."><plain>[101] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="1074" pm="."><plain>84 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1075" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1076" pm="."><plain>[102] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="1077" pm="."><plain>85 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1078" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1079" pm="."><plain>[103] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="1080" pm="."><plain>86 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1081" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1082" pm="."><plain>[104] </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="1083" pm="."><plain>87 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1084" pm="."><plain> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="1085" pm="."><plain>[105] </plain></SENT>
</text></td></tr></tbody></table></table-wrap></SecTag></floats-group></article>
